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ABSTRACT 
 
 
Engineering biomimetic scaffolds to encapsulate adipose-derived stem cells:  
A cell biology approach to regenerative treatments 
 
 
by 
 
 
Tracy N. Clevenger 
 
 
 
 
 The last decade has seen tremendous advances in the use of stem cell-
based therapies to treat injury and disease, yet there are many hurdles still to 
overcome. Tissue or organ-specific strategies have begun to emerge as our 
knowledge of stem cell biology and transplant biology increases. This thesis 
presents results aimed at understanding and improving cell based therapies for 
soft tissue repair. Defects in soft-tissue can occur by many means, including 
traumatic injury, tumor resection, and congenital causes. Current approaches to 
the treatment of these deficiencies include autologous fat transplantation, which 
falls short of optimal. There are numerous negative outcomes associated with 
this procedure, the most common of which is loss of transplanted volume; which 
occurs in 92% of cases.  
This thesis describes efforts to improve autologous treatments by utilizing 
the stem cell population present in transplanted tissue, adipose-derived stem 
cells (ASCs), and encapsulating them in an environment that supports survival, 
improving treatment options. The following chapters provide an in-depth overview 
of the development of a synthetic scaffolding system that supports the survival 
ix	
and differentiation of ASCs in vitro. By utilizing poly(ethylene) glycol (PEG) we 
were able to model a biomimetic environment and demonstrate that 
functionalization of inert PEG with different Arg-Gly-Asp (RGD)-containing 
peptides resulted in different levels of adhesion.  
 After the development of the scaffolding system we sought to further 
engineer capabilities of the system to provide the possibility for numerous 
applications using the same basic chemistry. Capitalizing on what is known about 
the remodeling of natural extracellular matrix (ECM) we were able to incorporate 
peptides that permit the degradation of the scaffolding after the stem cells 
differentiate. Selecting a cleavage sequence that is sensitive to proteinases that 
are secreted by mature adipocyte and not by undifferentiated ASCs we 
succeeded in creating a hydrogel that mimics a natural environment and is 
degradable upon the differentiation of ASCs to the desired cell types.  We have 
further demonstrated that ASCs encapsulated in this system are viable for 12 
weeks, both in vitro and in vivo. Although we examined just adipogenic 
differentiation in this work, due to the simple nature of the system it should be 
possible to systematically alter the incorporated components for applications of 
other cell types. This affords extensive possible targets for tissue regeneration 
utilizing a basic scaffolding system. Collectively, the work described here 
advances the understanding and application of stem cell based therapies for soft 
tissue repair and regeneration. 
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Chapter I.  
 
 
 
Strategies for bioengineered scaffolds that support adipose stem 
cells in regenerative therapies 
 
 
 
Abstract 
 
Regenerative medicine possesses the potential to ameliorate damage to 
tissue that results from a vast range of conditions, including traumatic injury, tumor 
resection, and inherited tissue defects. Adult stem cells, while more limited in their 
potential than pluripotent stem cells, are still capable of differentiating into numerous 
lineages, and provide feasible allogeneic and autologous treatment options for many 
conditions.  Adipose stem cells (ASCs) are one of the most abundant types of stem 
cell in the adult human.  Here, we review recent advances in the development of 
synthetic scaffolding systems used in concert with ASCs, and assess their potential 
use for clinical applications. This chapter has been submitted for publication as an invited 
review article in the Journal of Regenerative Medicine by Clevenger, TN., Luna, G., Fisher, 
SK., Clegg, DO. 
 
 
Adipose stem cells in regenerative medicine 
 Regenerative medicine is an immense field focused on the replacement, and 
regeneration of human cells and/or tissues to restore normal functions.[1,2]  The 
replacement of damaged or diseased tissue with functioning healthy cells is the 
	 2 
primary goal of this field.  The use of stem cells has become fundamental to its rapid 
expansion and the foundation for developing therapies to treat congenital defects, 
traumatic injury, and disease in a patient-specific manner through the use of 
autologous tissue.[3]  Since the first documented use of the term “regenerative 
medicine” and the isolation of human embryonic stem cells, efforts to develop 
synthetic scaffolds for use in conjunction with stem cells have increased 
significantly.[4-6]  The use of stem cells for regenerative treatments has achieved 
varying degrees of success with regards to replacing missing or damaged tissue, but 
progressive improvements have been brought about via recent efforts in tissue 
engineering.[7] 
 Indeed, a PubMed search for “regenerative medicine” yields more than 
30,000 publications since 1920.[8]  When the search is narrowed to include 
“regenerative medicine and stem cells” a list of 11,770 publications is returned.  
Refining this search still further by using key words such as “mesenchymal stem 
cells” yields only 1,148 publications.  Finally, using the phrase “regenerative 
medicine and adipose-derived stem cell” (ASC) produces a total of 156 publications 
from 2005 to 2016, an indication that research involving ASCs in the field of 
regenerative medicine remains in its infancy. 
Surgeons in the American Society of Plastic Surgeons preformed more than 
5.8 million reconstructive surgeries in 2015 alone to repair defects arising from tumor 
resection, traumatic injury, maxillofacial abnormalities, laceration repair, and scar 
revision.[9]  However, even the most common treatments show a significant and 
unpredictable loss of transplanted tissue volume over time.  Volume loss is a main 
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reason for treatment failure, and therefore a need exists for a microenvironment that 
produces repeatable, sustainable results over many years.  To this end, a 
biologically inert scaffolding system that can be tailored to the needs of individual 
patients and presents a means for maintaining tissue volume may prove to be a 
significant advancement over current treatments. 
Bone marrow-derived mesenchymal stem cells (BM-MSCs) are a type of 
adult stem cell commonly used in numerous therapies including the treatment of liver 
failure as a result of hepatitis B.[10] BM-MSCs have been approved for use in 
humans since 1995, and are currently being used in 272 clinical trials according to 
clinicaltrials.gov. Mesenchymal stem cells (MSCs) are multipotent cells that possess 
the ability to differentiate into various cell types, including adipogenic, chondrogenic, 
osteogenic, muscular, cardiac, and endothelial lineages.[11,12]  The International 
Society for Cellular Therapy (ISCT) uses three criteria to define MSCs regardless of 
their source: (1) plastic adherence in standard culture conditions; (2) expression of 
nonspecific surface markers CD105, CD 90, and CD73 and the absence of CD34, 
CD45, CD14, or CD11b, CD79α and HLA-DR; and (3) differentiation into 
osteoblasts, adipocytes and chondroblasts under specific stimuli in vitro.[13,14]  In 
contrast to pluripotent embryonic stem cells the benefits of using adult mesenchymal 
stem cells for treatments include the ability for autologous transplants and the 
absence of ethical controversies surrounding their use.  Adipose tissue provides an 
alternative to bone marrow-derived stem cells; it is a high-yield source of adult stem 
cells known as ASCs obtained predominately through rudimentary liposuction 
procedures.[15,16] 
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Adipose-derived stem cells share many similarities with BM-MSCs including 
their potential to develop into similar cell lineages, and have no clear distinction 
between the stem cell populations in terms of surface marker or gene 
expression.[13,17-20]  It has been suggested that ASCs can be distinguished from 
BM-MSCs by their expression of CD36 (F.A.T. - a protein involved in fatty acid 
metabolism), or CD49d (integrin α4 – a subunit of the integrin receptor for fibronectin 
and VCAM-1), as well as the lack of CD106 (VCAM1- a protein involved in the 
adhesion of vascular cells).  However, each of these proteins shows variability in 
expression patterns between specific ASC populations.[21]  Investigations into the 
gene expression profiles of BM-MSCs and ASCs found that 13.2% of 384 genes 
examined were differentially expressed between the two populations.  Although no 
identifying markers were specific to each population, genes more highly expressed 
by ASCs were mainly involved in cellular communication (FGF9, IL1R2, CCL3 and 
KDR) while those with higher expression in BM-MSCs were involved in WNT 
signaling and differentiation pathways (WNT11, WNT7B, and SOX6).[22] 
Adipose stem cells are 10 times more abundant than BM-MSCs in the tissues 
from which they are isolated.  Additionally, ASCs demonstrate a higher proliferative 
potential, show consistent growth rates in culture, and are procured from a minimally 
invasive procedure by comparison.[23,24]  Furthermore, ASCs are robust, capable 
of self-renewal, can be collected in large quantities and easily expanded in culture.  
These qualities identify ASCs as a promising source for use in therapeutic 
regenerative medicine.[25-28] 
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Over the last 18 years many techniques have been developed to create 
scaffolding materials that are compatible with stem cells as well as transplantation 
sites.  Scaffolds generated prior to cell seeding allow for the use of reagents typically 
considered “harsh,” thereby expanding the potential library of materials for 
therapeutic use.  Topical seeding of cells has been one approach used in the 
development of synthetic scaffolds in regenerative medicine, but often results in a 
very low penetration throughout the material, leading to a heterogeneous cellular 
distribution within the scaffold.[29]  Another tactic for the development of scaffolds as 
regenerative therapies is the use of decellularized extracellular matrix.  These 
scaffolds are generated from allogenic or xenogenic tissues and are popular for 
applications involving heart valves, blood vessels, tendons, and ligaments.  
Importantly, this technique most closely mirrors the mechanical and biological 
properties of human tissue.[30]  Complications from using this approach may arise if 
all cellular components of the donor tissue are not thoroughly removed prior to 
implantation, increasing the likelihood of immunological rejection, thereby requiring 
the long-term use of immunosuppressant drugs.  Cell encapsulation in natural or 
synthetic hydrogel matrix is yet another method used in scaffold engineering, since 
these frameworks can be designed to provide biomimetic environments that 
polymerize from a liquid to a solid polymer network under specific conditions.  By 
using a one-step procedure to encapsulate stem cells instead of topical cell seeding, 
a more homogenous cell density with exceptional cell viability is achieved.  Here, we 
provide an overview of the field by examining a collection of synthetic scaffolds 
currently used in conjunction with ASCs to treat defects of various tissue types. 
	 6 
Adipose stem cells in synthetic scaffolds for cartilaginous regeneration 
Cartilage is flexible connective tissue located in joints between bones, but 
regions of cartilaginous tissue also exist in the ear, nose, and rib cage.  Unlike bone, 
cartilage is not rigid; however, it is less flexible than muscle or other types of 
connective tissues, such as fat. Cartilage is important in providing flexibility to the 
skeletal system, a critical feature that allows for proper function.  Cartilage is 
primarily composed of chondrocytes, cells responsible for producing the extracellular 
matrix proteins required for the tissue’s unique mechanical characteristics.[31-34]  
Cartilage is unable to self-repair after blunt-force trauma, athletic injury, disease, or 
age-related degeneration.  The number of knee surgeries to repair articular cartilage 
damage each year in the United States increases by 5% annually.[35]  The natural 
lack of vascularization in addition to the minimal cell-to-cell contact restricts cartilage 
to only minimal spontaneous healing because of the slow dissemination of healing 
factors to distant cells.  Because of these characteristics, treatments frequently 
consist of surgically removing damaged tissue in order to reduce pain and restore 
function.[32,34,36]  A regenerative approach to cartilage replacement therapy 
involves the restoration of proper cellular morphology, and the prevention of further 
deterioration.  Current treatments, such as allografting, can carry small, but serious 
risks of infection and disease transmission while treatments such as autologous 
chondrocytic transplantations may result in degenerative changes accompanied by 
pain.[33,34,37] 
Adipose stem cells can be induced into chondrogenic differentiation in vitro by 
the combinatorial influence of growth factors, such as transforming growth factors β1 
	 7 
and β3, bone morphogenetic protein 4, and basic fibroblast growth factor.  Adipose-
derived stem cells provide several advantages over autologous chondrocyte 
treatments because they do not induce an inflammatory response, form new 
cartilage, and possess the potential for restoring long-term cartilage function.  The 
use of 3-dimensional (3D) scaffolds has gained momentum in the field of cartilage 
restoration because of their ability to overcome the growth inhibition typically 
observed in standard in vitro cultures.[38,39]  Synthetic platforms provide locations 
for ASCs to adhere, thereby providing an environment conducive for growth and 
proliferation.  Additionally, scaffolds have also been shown to promote differentiation 
and enable cells to achieve a cartilage-like morphology and express chondro-
specific molecules, such as collagen type II alpha1, and aggrecan.[40] 
Poly-lactide-co-glycolide (PLGA) is a copolymer approved for numerous 
therapeutic uses in humans by the Food and Drug Administration (FDA) since 2001.  
This copolymer may act as a stable or a biodegradable material depending on its 
formulation, and it possesses a permeable pore network that supports cell adhesion 
and proliferation.  Mehlhorn et al. (2009) showed that these scaffolds were suitable 
cell carriers for chondrocytes.  Furthermore, PLGA networks seeded with ASC-
chondrocytes showed excellent volume stability, and sufficient elasticity comparable 
to natural cartilage.[41]  These results suggest that PLGA may serve as an effective 
scaffolding system for chondrocytes derived from ASCs. 
Another avenue employs the use of fibrorous polyglycolic acid (PGA) 
stabilized by poly lactic acid (PLA).  Cui et al. (2009) demonstrated that this 
combination of polymers produced promising results during the initial attachment of 
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ASCs, and subsequent proliferation of chondrogenic-induced ASCs.  In addition, 
cells deposited cartilage-specific extra-cellular matrix (ECM) proteins within the 
polymer.  Degradation times of approximately 2 months in vivo appeared to match 
the natural mechanisms of new cartilage formation.  Thus, PGA/PLA in combination 
with ASCs may also serve as a synthetic scaffold for cartilage regeneration.[40] 
While PLGA and PGA/PLA comprise the bulk of synthetic polymers used for 
cartilage regeneration, other synthetic gels incorporate hyaluronic acid (HA), an 
important component of cartilage, into poly(ethylene) glycol (PEG) polymers.  
Unterman et al. 2012 showed HA-interacting PEG hydrogels improved cartilage 
tissue formation in vitro and in vivo in instances where HA was presented at a later 
stage of differentiation, subsequently resulting in increased chondrogenic 
phenotypes.[42]  Here, carefully considering properties of the native environment 
resulted in increased success by incorporating HA components that mimic the 
desired tissue.  This is an important case that demonstrated functionalization of a 
scaffold to more closely replicate a desired environment had a positive effect on 
graft viability.[43] 
3D cell printing, or bioprinting, has become an increasingly attractive option 
for the treatment of bone lesions as it provides a means to create scaffold structures 
that alleviate the limitations of the fields due to the complex 3D geometries 
associated with defects. The use of cells in prepolymer “bioink” allows a layer by 
layer deposition in a 3D construct that is analogous to tissues and organs.[44,45]  
This technique provides unique opportunities to develop complexly shaped scaffolds 
from synthetic material that encapsulate cells as shown by Lee et al (2014).[46]  The 
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fabrication of a structure with an ear shape with chondrocytes and adipocytes 
derived from adipose stem cell derived cells in a polycaprolactone (PCL) hydrogel 
demonstrated a successful composite tissue.  The efficient chondrogenesis and 
adipogenesis of the cell-printed structure resulted in a step forward for the 
practicality of 3D printing complex organs for tissue regeneration. 
 
Adipose stem cells in synthetic scaffolds for osteogenic therapeutics 
In contrast to cartilage, bone has regenerative capacity due to its inherent 
population of osteoblasts and osteoclasts (bone-forming and bone-resorbing cell-
types respectively).[47]  However, these processes are frequently perturbed in cases 
of trauma, disease, or tumor resection. Bone autografts, i.e., harvesting bone from 
one anatomic site and grafting into another site in the same subject, are one of the 
primary approaches currently used for bone augmentation in a variety of orthopedic 
and maxillofacial procedures.  Approximately 800,000 patients receive these grafts 
annually,[48] and while significant skeletal incorporation has been observed in these 
types of grafts many drawbacks still exist using this approach, such as delayed 
healing, a complete failure to heal, morbidity at donor sites, quantity restrictions, 
substantial financial costs due to additional procedures to harvest transplant tissue, 
and discomfort for the patient.[49-52] 
Collectively, focus has begun to shift towards the development of synthetic 
systems for use in conjunction with adipose stem cells to replace traditional bone 
grafts.  One study determined that PLGA is a viable scaffold for osteogenic 
differentiation of ASCs.  After two weeks of osteogenic induction, mineralized 
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nodular structures were observed by Alzarian Red and von Kossa staining, 
indicating successful calcification of the ECM.[53]  The use of PLGA scaffolds for 
osteogenic differentiation provides a viable polymer scaffolding option, however, 
further investigation is needed to determine what external cues may be necessary 
prior to graft implantation of this particular material, which has shown promise for 
applications involving chondrogenic and adipogenic lineages; indicating that the 
basic polymer supports numerous cell fates and must be modified to help direct 
differentiation. 
While polymers have proven to be useful in a variety of other fields, 
osteogenesis may require unique materials due to the highly specialized mechanical 
properties of natural bone.  Thus, regenerative osteogenic technology has begun to 
employ the use of titanium metal to create a space that facilitates the migration of 
implanted cells and their osteogenic differentiation.  Titanium is an inert biomaterial 
that possesses exceptional mechanical strength, is biocompatible, and therefore, a 
prime candidate for use in regenerative applications involving bone.  Adipose stem 
cells have shown compatibility with titanium systems, as well as displayed suitable 
cell adhesion.  As a scaffold, titanium enables adhesion and osteoblastic 
differentiation of ASCs in vitro, indicated by an increased deposition of alkaline 
phosphatase and osteocalcin (ECM proteins necessary for matrix mineralization) as 
well as calcification, confirmed by von Kossa staining.[54,55]  The ability of ASCs to 
acquire the proper phenotypic differentiation as well as produce an ECM and a 
mineralized matrix suggest titanium as an attractive material as a filler or support 
structure for bone ingrowth in regenerative medicine.[54] 
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Calcium phosphate ceramics (CPC) are another class of scaffolds used for 
bone regeneration.  These are promising synthetic materials due to their 
resemblance to bone mineral, their malleable bioactive properties, and their surface 
characteristics which support osteoblast adhesion, proliferation and differentiation in 
vivo.[56,57]  Most CPCs examined have been shown to be osteoconductive (growth 
of bone on a surface) while only certain types exhibit osteoinductive (recruitment and 
differentiation of immature osteocytes) abilities.  There is evidence, however, that 
increased mircoporosity increases the amount of bone inducing proteins secreted by 
ASCs in vitro.[58]  The similarities of CPCs to bone, along with their ability to induce 
bone growth and promote secretion of important proteins elevate these materials as 
an intriguing and exciting possibility for osteogenic therapies. 
While the similarities of CPC to bone have proven to be beneficial to 
osteogenic regeneration the use of decellularized bone (DCB) in combination with 
PCL shows even greater promise.  Polycaprolactone is a biodegradable polyester 
polymer used to circumvent the inability of 3D printers to use decelluarlized bone 
alone as a printing material.  The use of 3D printers to engineer scaffolding systems 
using PCL has shown enhanced adhesion of ASCs.  These cells exhibited 
significant upregulation of osteogenic genes such as osteocalcin, runx2, and 
osteonectin.  It was also demonstrated by Alzarian Red staining that ASCs on 
DCB:PCL materials showed increased calcification.  When scaffolds were implanted 
into calvarial defects in mice, DCB:PCL scaffolds invoked nearly twice the volume of 
regenerated bone in 12 weeks compared to PCL alone.[59]   
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The use of 3D printed PCL scaffolding without addition of natural components 
has also shown by varying the internal pore size of the scaffold it is possible to 
influence cell seeding of ASCs. By manipulating this parameter Temple et al 2014 
were able to achieve optimal vascular and osteogenic differentiation in 3D printed 
scaffolds.[60] This study also showed that maintenance of complex geometrical 
features such as maxilla and mandible bones maintain this porosity and therefore 
allow for cell seeding and vascularization similar to previous in vivo studies.  
Similar to PCL, polymers used in other regenerative studies, such PLGA can 
be blended with natural components to make them more amenable to 3D printing. 
Lee et al 2015 determined that by 3D printing PLGA scaffolds impregnated with 
bone morphogenic protein 2 and ASCs it’s possible to achieve mandibular 
regeneration.[61] The use of a small animal model of mandibular defects allows 
investigation of the potential for union of transplanted scaffolding with natural bone, 
within a site of segmental defect.  Similarly, Kao et al 2015 demonstrated that 
coating of 3D printed PLA with bio-inspired synthetic coatings increased the 
adhesion, proliferation, as well as the osteogenic and endothelial differentiation of 
ASCs in 3D structures.[62]  These simple modifications to synthetic 3D printed 
scaffolds may serve as the basis for effective delivery carriers in bone tissue 
engineering. 
 
Adipose stem cells in synthetic scaffolds for soft tissue regeneration 
Soft-tissue defects are relatively common, accounting for nearly 10% of all 
emergency department visits in addition to causes previously examined (i.e. trauma, 
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tumor resection).[63]  More than 100,000 breast reconstructions after mastectomy, 
and over 200,000 maxillofacial surgeries were performed in 2015 alone and it is 
predicted that there will be more than 12,000 new cases of soft-tissue sarcomas in 
the United States in 2016.[9,64]  The current treatment for many of these conditions 
is autologous lipotransfer, a procedure involving collecting fat tissue from a patient, 
minimally manipulating the resultant lipoaspirate and relocating it to the site of 
reconstruction.[65-68]  Although used widely, reports show that there is extensive 
variability of long-term lipotransfer graft survival, due to unpredictable degrees of 
resorption and tissue volume loss that can range from 20-90%.[29,69,70] 
Variations in soft-tissue graft survival have been attributed to many causes 
including a lack of local angiogenesis, sample preparation, as well as innate 
properties of the transplant site.[67]  In a national consensus survey, 92% of 
physicians stated that their patients experienced some degree of resorption, 52% 
reported a resorption rate of 50% or greater.[71]  Mature adipocytes constitute the 
majority of the transplant volume, and since these cells are in a terminally 
differentiated state, they lack the ability for self-renewal and proliferation.  The 
primary cause for transplant death is the lack of re-vascularization of the 
transplanted tissue.  Success rates are often reported to be as low as 20%, while 
successful transplants are commonly attributed to the relatively small population of 
ASCs present in the transplanted fat, and can be enhanced by increasing the 
number of stem cells transplanted.[67,72]  Thus, significant volume loss in these 
types of transplants provides motivation for finding ways to decrease the loss and 
thereby increase the likelihood of a successful transplant.  The recent development 
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of Cell Assisted Lipotransfer using concentrated ASCs as a lipoaspirate additive 
before transplantation leads to significantly improved results, specifically in terms of 
thickness gains observed during the first 6 months, and a reduction in thickness loss 
at 1 year.[73]  However, even cases using stem cell enrichment, marginal volume 
losses were still documented, and in most cases no gain of regenerated tissue was 
reported.[67]  Therefore, engineering synthetic scaffolds that can support the 
survival of the transplanted stem cell population while simultaneously promoting 
adipogenic differentiation has been proposed as a novel avenue for improving the 
success of these types of transplants. 
Various synthetic scaffolding materials have been examined to determine 
structural viability for stem cell survival and adipose tissue reconstruction.  Patrick et 
al. (2012) demonstrated that ASCs seeded into a PLGA scaffold and implanted 
subcutaneously into rats showed maximum adipose tissue formation after 2 months, 
but noted that between 3-12 months, a complete loss of reconstructed adipose 
tissue and degeneration of the PLGA scaffold occurred.[74]  This loss of tissue may 
arise from the degradation of the scaffolding, especially since signs of PLGA 
degradation were apparent as early as 1 month post-transplantation.  Thus, 
successful scaffolds for adipose tissue transplantation may require prolonged 
degradation times in order to allow for the maturation of regenerating tissue. 
Cho et al. 2005 demonstrated that implanting a support made of poly(glycolic 
acid) and poly(L-lactic acid) (PGA/PLA) before injecting pre-adipocytes provided 
enough support to maintain the volume of the implants and showed regeneration of 
the adipose tissue after 6 weeks in athymic mice.[75]  However, this approach 
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utilizes an implant primarily acting as structural support for ASCs that are injected in 
a solution.  Although stability of the transplanted volume was reported, there was no 
systematic method to measure pre-implantation volume, leading to difficulties in 
determining whether adipose growth was due to the implanted cells.  Additionally, no 
conclusive evidence was shown to indicate that the regenerated cells originated 
from transplanted ASCs.  In clinical applications it will be imperative to determine 
that the incorporation and differentiation of implanted cells replaces missing tissue. 
The use of blended copolymers has recently become increasingly popular for 
applications in therapeutic treatments.  The blending of poly(glycerol sebacate) 
(PGS), a biodegradable and biocompatible synthetic elastomer specifically designed 
to imitate the mechanical behavior of soft tissue, with PLA (to overcome the quality 
and flexibility concerns of using PGS alone) has shown promise.  Frydych et al. 
2015 showed that ASCs seeded onto the surface of a PGS/PLA scaffold exhibited 
significant amounts of cellular penetration and substantial collagen accumulation 
over 21 days.[76]  However, in vitro degradation assays determined that degradation 
appeared to progress too rapidly (50% loss after approximately 30 days) for this 
scaffold to support the growth of target tissue, a phenomenon also observed by 
Patrick et al.[74] 
Blending different scaffolding polymers provides the advantage of utilizing the 
positive attributes of each material.  Lin and colleagues used mixtures of gelatin 
sponges and polyglycolic meshes encased in microfilament polypropylene mesh to 
support adipose tissue regeneration using pre-differentiated ASCs.[77]  The gelatin-
polyglycolic mesh were observed to degrade completely within 60 days, however, 
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the polypropylene mesh is biostable and remains as a permanent resident of the 
transplant procedure.  In fact, it was demonstrated that after 6 months in vivo these 
scaffolds retained their shape, a trait attributed to the nondegradable mesh, while 
the newly formed adipose tissue occupied the space within the scaffold.[77]  This 
avenue is an improvement in terms of the longevity of engineered adipose tissue, 
however, this system is complex and requires lengthy in vitro cultures, thus it may 
prove too difficult to translate to clinical applications. 
While each of these synthetic scaffolds possess positive attributes, each 
neglects to consider important interactions of cells with their surroundings.  
Immediately following seeding into a synthetic scaffold, cells must be afforded sites 
of adhesion from which they are able to receive signals for survival, proliferation and 
differentiation.  Since these polymers are biologically inert it is critical to engineer 
attachment sites that provide favorable interactions between the ASCs and their 
surroundings.  Poly(ethylene) glycol (PEG) is a polymer that was approved for use in 
humans by the FDA in 1979, and is currently used in a myriad of applications 
ranging from food additives to pharmaceutical products and drug delivery 
systems.[78,79]  Recently, it was demonstrated that incorporation of Arg-Gly-Asp 
(RGD) variant peptides (linear RGD, cyclic RGD, and vitronectin derived RGD) into 
PEG based gels is a feasible approach to functionalizing an inert biomaterial.[80-84]  
These peptides provide sites for ASC attachment at the time of cell incorporation.  It 
was demonstrated that various adhesion peptides provided transplanted ASCs with 
enhanced directed adipogenic differentiation by comparison to systems that 
contained no attachment peptide.  Peptides considered to be highly adhesive lead to 
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smaller lipid vacuoles, and thus immature adipocytes.  However, peptides containing 
RGD derived from vitronectin (less adhesive) allowed ASCs to attach when 
incorporated into the hydrogel, while remaining rounded morphologically.[85]  This 
approach demonstrates that the initial environment encountered by ASCs may 
influence their ability to differentiate in 3D scaffolds. 
 
Conclusion 
 Despite its relative youth, the field of regenerative medicine is expanding 
quickly, encompassing exciting developments in the area of bioengineering, stem 
cell biology, and materials research.  Adipose stem cells hold enormous potential in 
this field.  The multipotency of ASCs provides the potential building blocks for the 
treatment and regeneration of damaged tissue.  Their relative abundance, and their 
ease of access, suggests ASCs may provide an improvement over other stem cells 
used in therapeutic treatments. 
The design of complex and smart materials able to interact with cells to direct 
their biological response and differentiation has been on the rise since the advent of 
tissue engineering.  It has been shown that the interactions of cells with their 
environment plays a critical role in their health and development.[86]  In order to 
regenerate and restore healthy tissue after an insult, disease, or defect the ability to 
direct implanted cells along specific pathways may prove to be paramount.  There 
are many avenues currently under investigation to determine the best method of 
combining ASCs and synthetic scaffolds to obtain an optimal graft or implant for the 
desired application.  Table 1 summarizes various synthetic matrices that have been 
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evaluated in the last 15 years for treatment of cartilage, bone and adipose tissue 
defects.  One of the most common polymers, PLGA, has been used for all three 
purposes, showing positive results when used in osteogenic applications, neutral 
results when used in chongrogenic repair and a notable loss of volume when applied 
to cases of adipogenic tissue growth.  This is a prime example of the diverse 
capability of synthetic polymers used with stem cell populations.  It is critical to 
consider the downstream consequences for all proposed scaffolding materials; 
specifically, scaffolding systems successfully used in one tissue type may not be 
yield similar results in another.  Mimicking the native environment of the target tissue 
is likely to play a significant role for the long-term survival of virtually all transplant 
scaffolds. 
Table 1. Summary of synthetic matrices used in combination with ASCs. 
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Indeed, it was recently demonstrated that various adhesion peptides provided 
transplanted ASCs with enhanced directed adipogenic differentiation by comparison 
to systems that contained no attachment peptide.[85]  The use of vitronectin derived 
attachment peptides promoted the development of larger lipid vacuoles, further 
suggesting that the interaction of the ASCs with their scaffolding may have a 
significance impact on the desired differentiation and health of implanted 
cells.[87,88]  Biomimetic PEG hydrogels may prove to be superior synthetic 
scaffolds for use in tissue reconstruction. [89-91] 
 
Future Perspectives 
 Applications of adipose-derived stem cell therapies have enormous potential 
for expanding the field of regenerative medicine.  Their ability to differentiate into 
numerous cell types, as well as their abundance, places ASCs at the forefront in the 
development of next-generation therapeutic treatments.  Vascularization of grafts 
and implants is another chief concern with respect to cell viability.  This is a critical 
issue in current approaches for regeneration and treatment, and thus an important 
factor to address when developing new synthetic scaffold systems.  The ability of 
ASCs to differentiate into endothelial cells along with a scaffold that supports a 
desired differentiation may increase the chances of achieving a scaffold that 
produces viable, long-lasting, vascularized tissue.[92-95] 
Transitioning scaffolding materials from the laboratory to clinical applications 
poses challenges that require further investigation.  For example, additional 
demonstration of long-term safety in preclinical animal models will be necessary.  
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This process is timely, labor-intensive, and expensive, however, the treatment 
benefits will outweigh the initial hurdles encountered in the exploration and 
development of synthetic scaffold for use as regenerative therapeutics. 
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Chapter II.  
 
 
Vitronectin-based, biomimetic encapsulating hydrogel scaffolds 
support adipogenesis of adipose stem cells 
 
 
 
Abstract 
Soft tissue defects are relatively common, yet currently used reconstructive 
treatments have varying success rates, and serious potential complications such as 
unpredictable volume loss and reabsorption. Human adipose-derived stem cells 
(ASCs), isolated from liposuction aspirate have great potential for use in soft tissue 
regeneration, especially when combined with a supportive scaffold. To design 
scaffolds that promote differentiation of these cells down an adipogenic lineage, we 
characterized changes in the surrounding extracellular environment during 
adipogenic differentiation. We found expression changes in both extra-cellular matrix 
(ECM) proteins, including increases in expression of collagen-IV and vitronectin, as 
well as changes in the integrin expression profile, with an increase in expression of 
integrins such as αVβ5 and α1β1. These integrins are known to specifically interact 
with vitronectin and collagen-IV, respectively, through binding to an Arg-Gly-Asp 
(RGD) sequence. When three different short RGD containing peptides were 
incorporated into 3D hydrogel cultures it was found that an RGD containing peptide 
derived from vitronectin provided strong initial attachment, maintained the desired 
morphology and created optimal conditions for in vitro 3D adipogenic differentiation 
of ASCs. These results describe a simple, nontoxic encapsulating scaffold, capable 
of supporting the survival and desired differentiation of ASCs for the treatment of soft 
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tissue defects. This chapter was published as Clevenger, T. N., Hinman, C. R., 
Ashley Rubin, R. K., Smither, K., Burke, D. J., Hawker, C. J., ... & Clegg, D. O. 
(2016). Vitronectin-based, biomimetic encapsulating hydrogel scaffolds support 
adipogenesis of adipose stem cells. Tissue Engineering Part A, 22(7-8), 597-609.   
 
Introduction 
 Soft tissue defects are caused by a number of sources including trauma, 
deep burns, tumor removal and liposarcomas [1-5]. Current standard reconstruction 
treatments of these defects include alloplastic implants and autologous fat 
transplants. While these methods have shown some success, they come with 
serious potential complication, including foreign body reaction, donor-site morbidity 
and migration of implants [2,6-8]. The likely occurrence of reabsorption in autologous 
fat transplants (currently the most commonly used treatment) makes this option less 
than optimal. It is believed that the benefits demonstrated by fat transplants are 
attributed primarily to a specific population of stem cells present in the tissue [9-14]. 
Therefore, a need exists for improved, consistent reconstruction strategies capable 
of treating these soft-tissue defects. 
 Adipose tissue, which is a rich source of easily isolated adipose-derived stem 
cells (ASCs), can be frequently harvested in large quantities utilizing standard 
liposuction procedures. These procedures have been shown to be effective and safe 
with low risk of donor-site morbidity [15-19]. Additionally, ASCs are readily obtained 
in significant quantities from a patient, are robust and capable of self-renewal.  ASCs 
are multipotent, mesenchymal stem cells that have the ability to differentiate down 
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various lineages, including adipogenic, osteogenic, chondrogenic, muscular, cardiac 
and endothelial, much like bone-marrow derived mesenchymal stem cells (BM-
MSCs) [2,20-22]. While ASCs and BM-MSCs share many similarities beyond their 
potential lineages, including the majority of their confirmed in vitro 
immunophenotypes [23,24], it has been shown that ASCs have a higher proliferation 
potential with a more consistent growth rate in culture [2,25-28] and are at least 10 
times more abundant than BM-MSCs [2,26,29].  Due to the accessibility of ASCs, 
the ease of cell culture and the short expansion times after isolation, it is feasible to 
use these cells to create autologous, patient-specific treatments, avoiding the 
potential complications of immune rejection. To reduce treatment outcome variability 
and promote targeted tissue regeneration, implanting only cells that provide the 
positive benefits (ASCs), in an engineered environment, is thought to be a viable 
approach. By implanting the desired cell population, volume loss and reabsorption 
should be kept to a minimum, as all cells present retain the potential to proliferate as 
well as differentiate. The cells in the scaffold will be influenced by the native tissue 
and may encourage the cells of the host’s tissue to regenerate [10,12,30-32]. A 
synthetic scaffold that promotes preferential differentiation and supports survival of 
this population of cells would be critical to the effectiveness of such a treatment. 
Such a scaffold would need to provide the necessary mechanical support for the 
graft as well as the long-term survival of the grafted cells.  
 Poly(ethylene-glycol) (PEG) hydrogels have promising potential to serve as 
basic scaffolding materials in regenerative medicine [1,3-5,16,18,21,23,26,33]. The 
inert backbone of PEG hydrogels, and the relative ease to functionalize sites 
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mimicking extracellular matrix (ECM) proteins to help direct cell fate make this type 
of hydrogel appealing for soft tissue reconstruction [6-8]. ECM proteins contain sites 
that cells can bind to and use to interact with their surrounding environment, 
including neighboring cells. The sites a cell interacts with can affect it in a variety of 
ways, including inducing proliferation, signaling a specific pathway for differentiation, 
or initiating apoptosis [9,11,13,14]. A binding site that numerous ECM proteins have 
been shown to contain is the Arg-Gly-Asp (RGD) sequence. Originally identified as a 
critical cell-ECM adhesion component in fibronectin (FN) [15,17,19], RGD has since 
been identified in numerous other ECM proteins, such as vitronectin, collagen I and 
collagen IV [20,21]. It has been shown that adipocytes in vivo are surrounded by an 
ECM that includes many similar proteins such as multiple collagens (types I and IV 
included), multiple laminins, fibronectin and others [23]. The expression levels of 
some of these proteins have previously been shown to change, in vitro, during 
differentiation of ASCs down various lineages [2,26-28]. During osteogenic 
differentiation increased deposition of collagens I and IV have been observed [2,26], 
while chondrogenic differentiation  shows increases in collagen II [10,12,31]. 
Changes in ECM expression of adipogenically differentiated mesenchymal cells 
isolated from bone marrow have been studied previously [16,18,21,23,26,33]. 
However, little work has been done examining adipogenesis in the more readily 
abundant cell population from fat lipoaspirate.  
Integrin receptors are one of the primary methods used by cells to recognize, 
and attach to, these RGD sequences and other peptide sequences in ECM proteins 
[2,19,22,34-36]. These receptors are heterodimeric transmembrane proteins made 
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up of an alpha and beta subunit. They interact with the surrounding ECM and relay 
messages from the extracellular environment to the cells, as well as from the cell to 
the ECM [24,34]. Based on previous work showing BM-MSCs change their integrin 
expression profile during other types of differentiation [25-28,37], we hypothesized 
that the integrin profile of ASCs being directed toward an adipogenic lineage will 
alter in response to a changing ECM environment. We further hypothesize that we 
can utilize various small integrin interacting peptides, incorporated into a 3-
dimensional scaffold, to promote adipogenic differentiation of this stem cell 
population.  
 
Materials and Methods 
Cell lines and culture 
Cells were isolated from two donors and a third line was purchased form Life 
Technologies (San Diego, CA). Donor cells were isolated from lipoaspirate by 
methods previously established [18,22,29,38-42]. Briefly, 1-4 liters of lipoaspirate 
were repeatedly washed with an equivalent volume of PBS containing 10 U/mL 
penicillin-streptomycin (Life Technologies) until the PBS layer was mostly clear. The 
washed lipoaspirate was then aliquoted into 225 cm2 flasks containing 0.15% 
collagenase type I solution (220.00 units/mg) (Life Techonologies) and 20 U/mL pen-
strep antibiotics. The flasks were incubated at 37°C on a slow shaker for 2 hours, 
with additional vigorous shaking every 15 minutes. The collagenase was neutralized 
by the addition of fetal bovine serum (FBS) (Atlas Biologicals, Fort Collins, CO) to a 
final concentration of 10%. The cell solution was then centrifuged at 1,000 x g for 10 
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minutes to pellet the stem cell-dense fraction. The supernatant, was removed and 
the cell pellet was resuspended in 160 mM ammonium chloride solution to lyse any 
red blood cells present. Cells were then centrifuged at 1,000 x g for 10 minutes, and 
the resulting pellets were resuspended in media containing 60% Dulbecco’s 
modified Eagle’s medium (DMEM) (Life Technologies) with 10% FBS and 40% 
MesenPRO medium (Life Technologies). Cells were passed through 50mL sterile 
vacuum 60µm Nylon cell strainers (Millipore, Billerica, MA), counted via 
hemocytometer, and then cryopreserved in a 3:2 mixture of DMEM+10% 
FBS:MesenPRO with 10% dimethyl sulfoxide (DMSO). For culturing and expansion, 
cells were thawed into 3:2 DMEM+10% FBS:MesenPro media and switched to 
100% MesenPRO 24-48 hours later. The cells were characterized using flow 
cytometery for immunophenotypes in accordance with guidelines set forth by the 
International Federation for Adipose Therapeutics and Science (IFATS) and the 
International Society for Cellular Therapy (ISCT)[43]. The cultures were determined 
to be CD44, CD90 and CD105 positive as well as CD45 and CD31 negative. All cells 
were passaged at least one time before use in experiments to ensure a population of 
only plastic adherent ASCs. Cells were transduced with a constitutive mCherry-
luciferase reporter plasmid (provided by Dr. Byron Hann, UCSF) and selected for 
using neomycin to obtain a population with only fluorescent expressing cells, to 
facilitate visualization of cells in 3-dimesional (3D) culture. All subsequent 
experiments were preformed on cells between passage 2 and passage 5. 
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Adipogenic Differentiation 
ASCs were dissociated using TrypLE Select (Life Technologies) at 37 °C for 
5-10 min and inactivated by dilution with MesenPRO, per the TrypLE protocol. The 
cells were spun down at 1,200 rpm and resuspended in MesenPRO then seeded 
into appropriate vessels at varying densities for 2D or 3D analysis. Cells in 2D 
cultures were grown in MesenPRO on uncoated tissue culture plastic until confluent 
and then switched to adipogenic differentiation medium. Cells for 3D cultures were 
treated in the same manner and then encapsulated in hydrogels at a high 
confluence, 2 x 106 – 2 x 107 cells/mL of hydrogel as explained below, and were 
placed directly into adipogenic differentiation media. Adipogenic differentiation 
medium consisted of alpha modified Minimum Essential Media (Sigma Aldrich, St. 
Louis, MO), supplemented with 10% FBS (Atlas Biologicals), 2mM L-Glutamine (Life 
Technologies), 100µM indomethicin (Sigma Aldrich), 10µg/mL insulin (Sigma 
Aldirch), 1µM dexamethasone (Sigma), 500µM 3-isobutyl-1-methylxanthine (Sigma 
Aldrich) and 10 U/mL pen-strep (Life Technologies) [30,32,39,40,44]. 2D and 3D 
cultures were allowed to differentiate for 21 days prior to analysis.  2D cultures were 
stained (see below) and imaged on an Olympus IX70 (Olympus, Shinjuku, Tokyo) at 
20X magnification. 3D cultures were stained with Hoescht 33342 (2ug/mL; 
Invitrogen), LipidTOX (1:150; Life Technologies) for detection of lipid vacuoles, and 
CellMask (1:150; Life Technologies) to enhance mCherry reporter and visualize cell 
bodies. 3D gels were then imaged on an Olympus Fluoview 1000 Spectral Confocal 
microscope. Images analyzed using Imaris software (Bitplane, South Windsor, CT). 
The “surface object” module was utilized to create a 3D representation of the stack 
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for each channel imaged and generate objects for the nuclei, lipid vacuoles, cellular 
membranes and the tagged peptides independently. Threshold settings were 
optimized for each channel to allow for unbiased counting of analyzed surface types. 
The distance tool in the software was also used to determine which cells contained 
lipids. The size of the lipid vacuoles was determined using size functions in the 
Imaris software.  
Immunocytochemistry 
ASCs at passage 2 were seeded at 2.3 x 104 cells/cm2 on uncoated tissue 
culture plastic 12 well plates and grown to 100% confluence in MesenPRO. Cells 
were then either fixed or switched to adipogenic differentiation medium and 
differentiated for 21 days. Cells were fixed through incubation with 4% 
paraformaldehyde in 0.2 M sodium cacodylate buffer for 10 minutes and stored in 
0.4% paraformaldehyde at 4°C for no more than 6 months. Cells were blocked using 
5% BSA and permeabilized using 0.2% TritonX-100 in 1X PBS for 1 hour at 4°C. 
Cells were stained overnight at 4°C with primary antibodies diluted in blocking buffer. 
(See Table 2 for a list of primary antibodies, and concentrations used.) Cells were 
subsequently washed with PBS and stained with AlexaFluor secondary antibodies 
(20µg/mL) and Hoescht 33342 (2ug/mL; Life Technologies) for 1 hour at room 
temperature before being imaged. 
3D Hydrogels 
A solution of 4-arm PEG-Thiol (Creative PEGWorks, Chapel Hill, NC) at 10 
wt% was prepared in 37°C cell culture media. A solution of divinyl sulfone (DVS)  
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Table 2. Primary Antibodies Used in This Study  
 
 crosslinker (Sigma Aldrich) was prepared in 4°C cell culture media. Custom ECM-
based peptides were synthesized by BioMatik (linearRGD and vitronectin-derived 
peptides) and received as a kind gift from the laboratory of Erkki Ruoslathi, UC 
Santa Barbara (cycloRGD) with FITC (liner RGD and vitronectin-derived) and FAM 
(cylcoRGD) fluorescent markers attached. Gels were functionalized with peptides at 
80 µM concentrations before DVS crosslinker addition. Cells were expanded on 
uncoated tissue culture plastic after transduction of the mCherry plasmid and 
selection with G418. After dissociation with TrypLE Select and pelleting, cells were 
resuspended in PEG/peptide solution and the DVS crosslinker was added at a 10:1 
ratio (DVS:PEG) immediately prior to plating. 50 µL of gel solution was then plated 
into each well of a Teflon mold. The polymerizing PEG solution was incubated 30 
minutes at 37°C then each gel was placed directly into appropriate culture media 
(adipogenic differentiation or MesenPRO) in separate wells of a 24-well plate. QGel 
Antibody Species Concentration 
(µg/mL) 
Manufacturer Catalog Number 
Integrin α1 Mouse Monoclonal 2 EDM Millipore, Temecula CA MAB1973Z-20 
Integrin α3 Mouse Monoclonal 2 EDM Millipore MAB1952Z-20 
Integrin α5 Mouse Monoclonal 2 EDM Millipore MAB 1956Z-20 
Integrin α6 Rat Monoclonal 2 EDM Millipore MAB1378-20 
Integrin αV Mouse Monoclonal 2 EDM Millipore MAB1953Z-20 
Integrin β1 Mouse Monoclonal 2 EDM Millipore MAB1951Z-20 
Integrin β4 Mouse Monoclonal 2 EDM Millipore MAB2060-20 
Integrin β5 Rabbit Polyclonal 2 EDM Millipore AB1926-20 
Fibronectin Rabbit Polyclonal 10 OneWorlLabs, San Diego CA C0195 
Collagen Type IV Rabbit Polyclonal 4 Abcam, Cambridge MA ab19808 
Laminin- α4 Rabbit Polyclonal 10 OneWorldLab, San Diego CA bs-11055R 
Collagen Type 1 Rabbit Polyclonal 10 Rockland Inc, Pottstown PA 600-401-103-0.1 
 
 
Vitronectin 
Rabbit Polyclonal 5 Abcam, Cambridge MA ab113700 
	 39 
without RGD (ref. 1004 QGel, Switzerland) was used following their recommended 
protocol. Briefly, ASCs were harvested and pelleted in the same manner as in the 
DVS-PEG gels and resuspended in 125µl of MesenPRO with peptide added at 80 
µM. One vial of QGel powder was dissolved in 375µl of Buffer A and quickly 
vortexed. The hydrogel mixture was then added to the cell suspension and quickly 
plated into molds in 50 µl aliquots and allowed to polymerize at 37°C for 30 minutes 
then immediately transferred into culture media.  
Adhesion Assay 
The ECM-based peptides were covalently conjugated to amine-modified 
Primaria 96well plates (Corning, 353872) via an N-hydroxysuccinimide ester (NHS) 
NHS-PEG12-Maleimide bi-functional linker (Thermo Scientific Pierce, Carlsbad, Ca; 
PI22112). NHS groups on the linker were reacted with amines on the plates to form 
amine bonds, and consequently attach the linker to the plates through incubation 
with 100 µM NHS-PEG12-Maleimide in PBS for 30 minutes at room temperature. 
Peptides were diluted to 20 µg/mL in PBS and conjugated overnight at 4°C to react 
the free cysteine on the peptides with the malemide groups on the linker and create 
thioester bonds [1,3-5,45]. Plates were then blocked for 2 hours at room temperature 
with 1%BSA and washed with PBS to remove excess BSA. ASCs were detached 
from tissue culture plastic after expansion using TrypLE Select (Life Technologies), 
diluted for inactivation in serum free cell culture media, pelleted, resuspended in 
serum free media and then stained in suspension with Hoescht 33342 (2 ug/mL; 
Invitrogen) for 10 minutes, at room temperature for subsequent nuclear visualization. 
Cells were counted on a hemocytometer then seeded, in triplicate for each peptide, 
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at 2.9 x 104 cells/cm2 [6-8,15] and allowed to adhere to the modified plates for 3 
hours at 37°C. It was determined that a shorter amount of time did not allow for 
strong enough adhesion to withstand even gentle washing. Non-adherent cells were 
removed by very gently washing plates three times with room temperature PBS. A 
negative control of no linker/no peptide and linker/no peptide were included. Each 
well was imaged immediately after the 3-hour attachment period on an Olympus 
IX70 fluorescent microscope (Olympus) at 10 X magnification at the center of each 
well. Fluorescent nuclei were counted and cell area was calculated using ImageJ 
software (National Institute of Health). Statistical analysis was performed using a 
two-tailed Student’s t-test for this and all subsequent assays.  
Culture of ASCs on Full Length ECM Proteins  
All proteins were used at a final concentration of 10 µg/mL. Protein dilutions 
were made fresh and 24-well culture plates were coated overnight at 4°C. Laminin 
(Sigma Aldrich L4544), fibronectin (R&D systems, Minneapolis, MN; 4305-FN-200), 
vitronectin (R&D systems; 2308-VN-050), collagen type I (R&D Systems; 6220-CL) 
and collagen type IV (Millipore; CC076) full length proteins were used. Passage 4 
ASCs were thawed from cryopreservation and seeded at a density of 3 x 104 
cells/cm2. Cells were harvested at days 1, 3, 5, and 7 using TrypLE Select and 
counted using the Scepter Handheld Automated Cell Counter (Millipore). Media was 
harvested from the cultures at each time point before cell harvest and snap frozen in 
liquid nitrogen, for ELISA testing.  Adiponectin, leptin, basic fibroblast growth factor, 
vascular endothelial growth factor, hepatocyte growth factor (Life Technologies) and 
stromal cell derived factor-1 (R&D Systems) ELISA kits were used according to the 
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manufacturer’s protocol to assay the amount of each factor present in the spent 
media at the various time points.  
Proliferation Assay 
QGel was prepared as described in the 3D hydrogel section above. ASCs 
were seeded at a density of 10 x 106 cells/mL and cultured after polymerization in 
24-well plates in MesenPRO media for 7, 14 and 21 days. At each time point, as well 
as on day 0, QGels were placed in individual 1.5mL Eppendorf tubes and frozen at -
80°C. Once all samples had been collected, QGels were digested using Proteinase 
K (0.5 mg/mL) overnight at 60°C and DNA content was determined following the 
CyQUANT NF Cell Proliferation Assay protocol for non-adherent cells (Life 
Technologies). Peptide functionalized PEG-DVS hydrogels were made as described 
in the 3D hydrogels section above. Cells were seeded at a density of 10 x 106 
cells/mL and cultured in MesenPRO media for 0, 7, 14 or 21 days. Because the 
PEG-DVS gels were unable to be digested to quantify DNA content the hydrogels 
were instead stained with Hoescht, to visualize nuclei, and imaged on an Olympus 
Fluoview Spectral Confocal microscope. The average number of nuclei for each 
peptide condition, in three fields, for each of three individual gels was determined at 
desired time points using Imaris software (Bitplane, CT, USA).  The “spots” module 
was used to create a 3D image of the 150 µm z-stacks and a spot was created 
based on intensity value of nuclei visualized in the DAPI channel, allowing 
determination of individual nuclei. Threshold settings were optimized and used for 
impartial counting of nuclei, independent of peptide condition. Nuclei counts were 
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averaged for each gel and then for each peptide condition. A Student’s t-test was 
used to determine statistical significance. 
Results 
As previously described, ASCs isolated from human lipoaspirate can be 
differentiated down multiple lineages including adipogenic, chondrogenic, osteogenic 
and endothelial [2,9,11,13,14,22,46]. The differentiation process of many cell types 
has been shown to be affected by the extra-cellular environment 
[9,11,13,15,17,19,47,48]. During differentiation, the surrounding extracellular 
environment must change to properly support the new, maturing cell population. In 
an effort to understand this process during adipogenic differentiation, we used 
immunocytochemistry to examine the expression of ECM proteins and integrin 
subunits in undifferentiated ASCs and in ASCs that had undergone adipogenic 
differentiation for 21 days. As shown in Figure 1A certain ECM proteins, such as 
collagen I and vitronectin, were expressed at relatively low levels by undifferentiated 
ASCs. After 21 days of adipogenic differentiation there was a change in the 
expression pattern of these proteins as well as an increase in overall expression. 
Other proteins, such as collagen IV, laminin-α4 and fibronectin were not found to be 
present in undifferentiated ASC cultures, but could be readily detected in the ASC-
derived adipocyte population. Still other ECM proteins such as Elastin (not shown) 
were detected, but showed no change in immunoreactivity after adipogenic 
differentiation.  
The increase in expression of select ECM components, specifically collagen 
IV, vitronectin and fibronectin, which were not detected in undifferentiated ASCs, 
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supports the idea that the differentiated cells demonstrated increased utilization of 
integrin receptors that recognize Arg-Gly-Asp (RGD) sequences present in all of 
these proteins. [20,21,49-53] Laminins containing the α4 subunit are recognized by 
different integrins not involved in RGD signaling. There are at least eight known 
integrins that can bind to laminin, [23,54] and adipocytes use a small number of 
these [33]. 
Figure. 1. Analysis of ECM protein and integrin expression in ASCs before and after adipogenic 
differentiation. (A) ECM proteins indicated (green) were detected by immunocytochemistry in 
undifferentiated ASCs (left) and ASCs subjected to adipogenic differentiation for 21 days (right). 
Nuclei (blue) were detected by Hoechst staining. Scale bar=50mm. (B) Integrin subunits 
indicated (green) were detected by immunocytochemistry in undifferentiated ASCs (left) and 
ASCs subjected to adipogenic differentiation for 21 days (right). Nuclei (blue) were detected by 
Hoechst staining. Scale bars = 50 mm. ASCs, adipose-derived stem cells; ECM, extracellular 
matrix. 
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While integrin expression of BM-MSC derived adipocytes has been examined 
previously [26], the expression of integrins in adipocytes derived from lipoaspirate, 
compared to their undifferentiated counterparts, has yet to be examined fully. Using 
immunocytochemistry, we characterized the expression of integrin subunits in 
undifferentiated ASCs and ASC-derived adipocytes that had been differentiated for 
21 days (Figure 1B).  We detected several integrin subunits in ASC-derived 
adipocytes but not in undifferentiated ASCs (specifically α1, α5, α6, αV, β4, and β5), 
as well as some integrin subunits (α3 and β1) that were expressed in both the 
differentiated and undifferentiated cells, although at higher levels in the ASC-derived 
adipocytes than the undifferentiated ASCs. In addition, there were subunits that 
were found to have no discernable change in expression after 21 days of adipogenic 
differentiation, such as α2, α4 and β3 (not shown). These results indicate that both 
ECM and ECM receptors are dynamically regulated during adipogenic 
differentiation. 
To examine how the ECM environment might effect the adipogenic 
differentiation of ASCs, we cultured cells grown on full-length proteins in 2D and 
assessed their proliferation and expression of adipogenic and endothelial markers 
over time (Figure 2). These ECM proteins were selected based on changes in 
expression of ECM proteins and integrins observed during adipogenic differentiation 
of ASC cultures, with the goal of mimicking the normal adipose ECM environment 
and promoting this pathway.  Proliferation of undifferentiated ASCs cultured in 
maintenance conditions on selected ECM proteins was assessed over one week. In 
general, cell proliferation was relatively slow in the low serum media, both on ECM  
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Figure. 2. Effects of full-length ECM proteins on ASCs. (A) Proliferation on different substrates 
was quantified (*p < 0.05) (B) Secretion of adipogenic factors (adiponectin and leptin) by 
ASCs cultured on different ECM proteins was quantified by ELISA at day 1 (dark bars) and 
day 14 (light bars). Secretion of bFGF and SDF1- a (C) and VEGF and HGF (D) by ASCs 
cultured on different ECM proteins was quantified by ELISA over time (***p<0.001; **p < 0.01; 
*p < 0.05). bFGF, basic fibroblast growth factor; Col I, collagen I; Col IV, collagen IV; FN, 
fibronectin; HGF, hepatocyte growth factor; LM, Laminin; SDF-1a, stromal cell-derived factor 
1a; VEGF, vascular endothelial growth factor; VN, vitronectin. N=3 
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proteins as well as tissue culture plastic (control). However, ASCs cultured on 
collagen IV showed a significant increase in cell number compared to the control 
(Figure 2A) (p<0.05). The only protein that showed a significant, although slight, 
increase in proliferation at day 7 compared to uncoated tissue culture plastic was 
fibronectin (p<0.05). All other ECM proteins tested supported proliferation rates 
similar to that of ASCs cultured on untreated tissue culture plastic. Next, we 
examined secreted factors important in adipogenic differentiation (specifically leptin 
and adiponectin) using ELISA assays. We found that after 14 days of culture in 
maintenance conditions on selected ECM proteins ASCs grown on all proteins 
secreted significantly higher levels of both leptin and adiponectin relative to ASCs 
cultured on untreated tissue culture plastic (Figure 2B) (p<0.001). ASCs cultured on 
fibronectin or laminin secreted the highest levels of adiponectin and cells on collagen 
IV secreted the lowest levels. Secretion of four angiogenic factors was also 
investigated: basic fibroblastic growth factor (bFGF), stromal cell-derived factor 1 
(SDF-1α) (Figure 2C), vascular endothelial growth factor (VEGF), and hepatocyte 
growth factor (HGF)(Figure 2D). Because these factors mediate the formation of 
new blood vessels, recruit endothelial progenitors, and stimulate vasculogenesis and 
mitogenesis, their expression during adipogenic differentiation would be useful for 
eventual clinical applications using ASC-derived adipocytes in tissue grafts and 
transplants. Results showed that secretion of bFGF and HGF was higher at day 5 on 
all protein substrates as compared to uncoated control.  SDF-1α levels were higher 
on protein substrates at day one (especially Collagen I), but did not significantly 
differ from uncoated controls at day 5. VEGF levels decrease over time, but were 
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higher, compared to uncoated controls, after 3 days on all substrates. Taken 
together, these results show that ECM protein could be utilized to improve 
adipogenic differentiation in a 3D culture. 
Because four out of the five ECM proteins examined above contain functional 
RGD peptide sequences, we chose 
to investigate the ability of different 
RGD-containing peptides to promote 
adhesion of ASCs. We investigated 
peptides with varying adhesivity: a 
cyclized RGD peptide (cycloRGD) a 
linear RGD peptide (linearRGD), and 
a vitronectin-derived RGD peptide 
(VnRGD) (Figure 3A). It has been 
previously shown that cells adhere to 
cycloRGD significantly more strongly 
(10 times) than to the linearized form 
[55]. The VnRGD peptide was 
derived from the full-length vitronectin 
protein sequence, containing the 
RGD sequence [56] based on work 
done previously [57]. To investigate 
the adhesive properties of each RGD 
peptide on ASCs, we performed 3 
FIG. 3. ASC Adhesion and spreading on RGD 
peptides. (A) Sequence of peptides. (B) Average 
number of cells that attach to peptides in two-
dimensional culture, after 3h, showing varying 
adhesion, compared to no-peptide control. (C) 
Average area of cells after attachment on various 
pep- tides showing extent of spreading after 3h of 
attachment compared to no-peptide control (**p < 
0.01, ***p < 0.001).  
	 48 
hour-long adhesion assays. We found that significantly greater numbers of ASCs 
adhered to cycloRGD compared to linearRGD (p=0.04), but similar numbers of 
ASCs adhered to VnRGD and cycloRGD (p=0.55) (Figure 3B). ASCs adhered to 
each RGD peptide in significantly greater number compared to the no peptide 
control (p<0.001). The extent of the ASC spreading on the RGD peptides, which is 
indicative of the strength of adhesion of the ASCs on the surface, was also 
quantified (Figure 3C). We found that individual ASCs spread over significantly 
greater distances when plated on cycloRGD compared to linearRGD, VnRGD and 
no-peptide controls (p=0.008, p=0.009, and p<0.001 respectively). However, no 
difference in the amount of spreading was observed when comparing ASCs assayed 
on linearRGD and VnRGD (p=0.85). These results indicate that cycloRGD allows for 
both strong initial attachment and spreading of ASCs and that the VnRGD peptide 
provides good initial attachment, but less cell spreading of ASCs. Overall, these 
three RGD peptides were found to support varying degrees of ASC adhesion and 
cell spreading, giving us the ability to investigate the effects of varied adhesion on 
adipogenic differentiation of ASCs in 3D. 
We next incorporated the RGD peptides into 3D hydrogels to examine 
possible effects on proliferation and adipogenic differentiation of the ASCs. We 
initially used QGel, which is a commercially available gel that has previously been 
used successfully in in vivo studies [58] to examine whether peptides could be 
incorporated, retained, and whether ASCs could survive and be differentiated down 
an adipogenic lineage in 3D. Peptides with a free cysteine were added into QGel 
solution just before cells were encapsulated at a concentration of 80 µM. Using a 
	 49 
CyQUANT assay to determine the DNA content of the QGels after 21 days in 
maintenance media, it was shown that the undifferentiated ASCs could in fact 
survive in 3D cultures and that the cycloRGD peptide provided the best condition for 
the ASCs to attach and proliferate in the Qgels (Figure 4A) with significantly more 
growth at day 21 than VnRGD and no peptide conditions (p=0.0002 and p=0.0018). 
All three peptides supported proliferation of ASCs in 3D cultures more than gels 
without attachment sites. After culture for 21 days in QGel with adipogenic 
Figure. 4. QGel 3D Hydrogel proliferation and adipogenic differentiation. (A) Proliferation of the 
ASCs in maintenance conditions in 3D culture as determined by a CyQUANT assay. (B) 3D 
reconstructions of ASCs adipogenically differentiated for 21 days in Qgel containing various 
attachment peptides. (C) The average number of nuclei visualized per field showing the overall 
number of cells present after 21 days of adipogenic culture. (D) The percent of total cells present 
in each field that are associated with a lipid vacuole. (E) The average size of all the lipid vacuoles 
present for each condition (*p < 0.05, **p < 0.01, ***p < 0.001). 3D, three-dimensional. 	
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differentiation media, all three peptides were still present, as shown by continued 
presence of fluorescent signal (Figure 4B; green). Cells were detected under all 
conditions, including those cultured in QGel without peptides, as shown by staining 
for nuclei. Likewise, all conditions allowed for adipogenesis, as shown by a LipidTOX 
stain for neutral lipids in lipid vacuoles (Figure 4B; orange). Cell membranes were 
visualized using the fluorescent reporter transfected into the cells before 
encapsulation and enhanced for clarity using CellMask (Figure 4B; red).  
Quantification of cell numbers showed that all gels contained about the same 
number of cells, regardless of the peptide (Figure 4C). While all conditions allowed 
for adipogenic differentiation, it was found that the cycloRGD peptide yielded a 
significantly lower percentage of cells containing lipid vacuoles (p=0.04) when 
compared to the VnRGD condition (Figure 4D).  The percentage of cells containing 
lipid vacuoles was similar for ASCs differentiated with the linearRGD, VnRGD and 
QGel without peptides. Using Imaris software we were also able to measure the 3D 
area of the lipid vacuoles and found that the lipid vacuoles formed by ASCs 
differentiated with cycloRGD were significantly smaller than those formed in QGel 
without peptides (p=0.04) (Figure 4E).  The size of the lipid vacuoles formed by 
ASCs differentiated with linearRGD, VnRGD and QGel without peptides were not 
significantly different in size.  
We next incorporated RGD peptides in a simple encapsulating, PEG-based 
hydrogel with a DVS cross-linker (PEG-DVS)[59], and tested proliferation and 
adipogenic differentiation of ASCs. ASCs were seeded into these PEG-DVS gels at 
10 x 106 cells/mL, with consistent peptide concentrations as in the QGels. 
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Undifferentiated ASCs were grown in the PEG-DVS gels, in MesenPRO, for up to 21 
days and imaged using a confocal microscope to determine the rate of proliferation 
in each of the peptide conditions. At day 21 it was found that the linearRGD peptide 
actually supported proliferation significantly better than all other peptide, and no 
peptide conditions (cycloRGD p=0.009, VnRGD p=0.004, H2O p=0.0001) (Figure 
5A). In this hydrogel system the cycloRGD and vitronectin-derived supported the 
Figure. 5. PEG-DVS 3D hydrogel proliferation and adipogenic differentiation. (A) Proliferation of 
the ASCs in maintenance conditions in 3D culture over 21 days. (B) 3D reconstructions of ASCs 
adipogenically differentiated for 21 days in PEG- DVS gels containing various attachment 
peptides. (C) The average number of nuclei visualized per field showing the overall number of 
cells present after 21 days of adipogenic culture. (D) The percent of total cells present, in each 
field that are associated with a lipid vacuole. (E) The average size of all the lipid vacuoles present 
for each condition (*p<0.05, **p < 0.01, ***p < 0.001). DVS, divinyl sulfone; PEG, poly(ethylene-
glycol). 	
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same (limited) proliferation and both were more supportive than no peptide. When 
ASCs were seeded in PEG-DVS gels and grown in adipogenic media for 21 days, all 
peptide conditions, including the gels without peptide, supported adipogenesis 
(Figure 5B), as indicated by staining of neutral lipids with LipidTOX (Figure 5B; 
orange). Additionally, high levels of peptide incorporation were still apparent after 21 
days in culture, as assessed by the visualization of the FITC/FAM tag on the 
peptides (Figure 5B; green). Unlike with the QGel system, we observed a difference 
in the total number of cells present in the PEG-DVS systems after 21 days of 
adipogenic differentiation, with a significantly greater number of cells present in the 
VnRGD system compared to the linearRGD system (p=0.004) (Figure 5C). Also 
differing from the results using QGel, we found that there was no significant 
difference in the percentage of cells containing lipid vacuoles (Figure 5D).  However, 
the size of the lipid vacuoles in the VnRGD and linearRGD systems were both 
significantly larger compared to the size of the lipid vacuoles in the cycloRGD 
system (VnRGD p=0.001, linearRGD p=0.04) (Figure 5E). Overall, our results with 
the PEG-DVS system agree with the Qgel data in that the VnRGD peptide was the 
most supportive of adipogenic  
 
Discussion 
Here we have shown that the ECM profile of ASCs changes over 21 days of 
adipogenic differentiation. Increases in collagens type I and type IV, as well as in 
vitronectin and fibronectin indicate a likely increase in RGD sites throughout the 
culture. This change in proteins present outside of the cells correlates to the 
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changing integrin profile of the cells. Integrin α1β1 has been shown to be involved in 
attachment to collagen IV and laminins containing the α4 subunit [27,60], while 
α3β1, α6β1 and α6β4 have all been shown to interact specifically with laminins [60-
62]. αVβ5, αVβ1, and α5β1 along with several other integrin heterodimers have been 
shown to interact with RGD sequences from varying ECM proteins, including 
collagen I, fibronectin and vitronectin [27,63,64]. The increase of each of these 
subunits in adipogenically differentiated cultures along with increases in ECM 
proteins that they are able to interact with supports the hypothesis that these 
integrins may be important to the differentiation process.  
It has been found that BM-MSCs adipogenically differentiated for 21 days 
only showed a significant increase in α6 integrin subunit and significant decreases 
most notably in α3 and β4 [26]. While there are a few common changes of integrin 
subunit expression between BM-MSCs and ASCs (like the increase in α6) there are 
more notably some potentially important differences. One such difference is the lack 
of increase in α5 and αV in the BM-MSCs. β1 can dimerize with a large number of α 
subunits, including α5 and αV, which are both used for binding of RGD sequences in 
fibronectin. The increase in expression we observed in β1, coupled with the 
expression of α5 and αV in the derived adipocytes further supports the importance of 
interaction with RGD containing ECM proteins in adipogenic differentiation of ASCs. 
Such changes can be potentially utilized in the design of a synthetic 3D environment 
to enhance adipogenic differentiation. 
We found that ECM protein substrates in a 2D environment increases the 
secretion of factors favorable for adipogenic differentiation (relative to uncoated 
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controls) such as adiponectin and leptin [65-69]. Other secreted factors important in 
angiogenesis and vasculogenesis, specifically bFGF, sDF1α, VEGF and HGF [70-
73] were also increased. These data are particularly important, as the survival of a 
3D tissue graft in vivo will most likely require the formation of some vasculature in 
order to bring blood and essential nutrients to the cells present in the tissue graft. 
While the expression of these factors is clearly essential for developing tissue grafts, 
it’s also important to keep in mind that ASCs themselves are capable of 
differentiating into endothelial cells [46,74], which would allow these cells to 
potentially survive in vivo by differentiating into both adipocytes and endothelial cells 
capable of creating their own vasculature.  
By examining the important links between how the changing extracellular 
environment of differentiating ASCs affects the expression of integrins we were able 
to determine candidate peptides for incorporation into our 3D structures. Based on 
the expression of multiple ECM proteins that contain RGD sequences in the 
adipogenically differentiated cultures we decided to examine how different RGD 
peptides might affect adipogenic differentiation in a 3D system. Knowing that mature 
adipocytes are natively found in a relatively soft environment [75], we chose three 
RGD-based peptides to provide different strengths of adhesion to examine the affect 
of this initial adhesion strength on the undifferentiated ASCs for their eventual 
adipogenic differentiation. The initial interaction of these cells with their environment 
may provide important cues for their eventual differentiation [9,13]. We found that 
the greatest number of undifferentiated ASCs adhered to cycloRGD although this 
was not significantly greater than the number of cells adhered to VnRGD. The 
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difference between the cycloRGD and VnRGD peptides was seen in the extent to 
which the ASCs spread out during the adhesion period. The size of the 
undifferentiated ASCs grown on the VnRGD over 3 hours was less than that on the 
cycloRGD and similar to cell spreading on linearRGD. Overall, while both cycloRGD 
and VnRGD provide good sites for initial attachment of undifferentiated ASCs, the 
VnRGD peptide keeps the cells in a more rounded formation, which may be 
favorable for adipogenic differentiation [76,77].  
The strong initial adhesion and reduction in spread morphology of the 
undifferentiated ASCs on the VnRGD peptide conditions was found to be beneficial 
to adipogenic differentiation in a 3D environment as well, in both the commercially 
available QGel as well as a novel formulation of a PEG-DVS hydrogel. We saw that 
in the QGel the number of cells with lipid vacuoles was significantly lower in the 
cycloRGD gel, which promoted spreading. While the percentage of lipid vacuole-
containing cells did not differ in the PEG-DVS gels between the different peptides 
used, the size of the lipid vacuoles did vary with cells cultured in the VnRGD-
containing gels typically forming significantly larger lipid vacuoles. This production of 
larger lipid vacuoles is potentially due to the more rounded morphology of the cells 
differentiated in the VnRGD-containing hydrogels.  
When comparing the commercially available QGel and the PEG-DVS gels we 
found that while both systems incorporate and maintain the presence of the RGD 
peptides well, the PEG-DVS gels seem to be more supportive of adipogenic growth 
and differentiation of ASCs compared to QGel. It may be that while the basic 
thiolene chemistry employed in both gels is acceptable for differentiation of ASCs 
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into adipocytes, the somewhat different PEG-DVS gel system, provides a slightly 
more conducive environment for the growth and differentiation of ASCs to 
adipocytes, possibly due to fewer crosslinking events.  
We were able to determine that when ASCs isolated from lipoaspirate were 
encapsulated into a PEG based hydrogel they were able to not only survive for at 
least 3 weeks, but also able to proliferate in an undifferentiated state as well as 
differentiate into adipocytes. The incorporation of RGD-based peptides into these 
gels affected the efficiency of adipogenic differentiation. Specifically, we found that a 
strongly adhesive peptide, cycloRGD, may not provide ideal adipogenic inducing 
interactions for ASCs in vitro. VnRGD, however, may create the most inductive 
environment for adipogenic differentiation; while it supported significant initial 
adhesion of undifferentiated ASCs, it still allowed the cells to remain more rounded. 
It also proved to offer the most beneficial environment for adipogenic differentiation 
in 3D hydrogels, with cells differentiated in its presences showing large lipid 
vacuoles, indicating more mature adipocytes.  These data show the ECM-based 
attachment sites provided within a 3D environment have a direct effect on the 
efficiency of adipogenic differentiation of ASCs in vitro. While these conditions may 
not precisely reflect the in vivo environment, they represent an important foundation 
to developing potential treatments. The incorporation of RGD-containing peptides 
into tissue grafts might later be utilized for improved adipogenic differentiation of 
ASCs, with the ultimate goal of soft tissue reconstruction in vivo.  
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Chapter III. 
 
Cell mediated remodeling of biomimetic encapsulating hydrogels 
achieved by adipogenic differentiation of adipose stem cells 
 
 
Abstract  
 One of the most common regenerative cellular therapies is autologous fat 
grafting, which can suffer from unexpected volume loss and/or reabsorption of the 
graft.  One approach to this problem is to isolate adipose stem cells (ASCs), and 
deliver them in an engineered, synthetic environment that supports cell survival, 
differentiation, and integration after transplant. We describe an encapsulating, 
biomimetic poly(ethylene)-glycol (PEG) hydrogel, with embedded peptides that 
provide sites for attachment and biodegradation. We sought to develop a long-
lasting gel that would remodel upon differentiation of ASCs to adipocytes to provide 
spaces within the gel supportive of cell survival and differentiation. PEG hydrogels 
containing an Arg-Gly-Asp (RGD) attachment sequence in addition to a matrix 
metalloprotease 3 / 10 cleavage site (MMPc) supported ASC survival and showed a 
regulated remodeling, which is triggered by adipogenic differentiation.  RGD-MMPc 
hydrogels with encapsulated ASCs showed an increased number and area of 
lacunae or holes, only after ASCs were differentiated to adipocytes.  Image analysis 
of ASCs in RGD-MMPc gels showed larger Voronoi domains, while cell density 
remained unchanged. Differentiated adipocytes residing within these newly 
remodeled spaces express proteins and mRNAs indicative of adipocytic 
differentiation. A biomimetic hydrogel scaffold where remodeling of the gel is 
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triggered by adipogenic differentiation may be useful in soft tissue regeneration. This 
work was completed by Tracy N. Clevenger, Gabriel Luna, Daniel Boctor, Steven K. 
Fisher and Dennis O. Clegg. 
 
Introduction 
The development of biocompatible materials has helped advance the field of 
tissue engineering by providing new cellular platforms for the promotion of tissue 
regrowth.[1]  Many fields in regenerative medicine, including the treatment of chronic 
wounds, stand to benefit significantly from advances in biomaterial engineering.  It is 
estimated that 1-2% of people in developed countries will experience a chronic 
wound in their lifetime, and that in the US alone 6.5 million patients suffer from 
chronic wounds.[2,3]  Additionally, soft-tissue injuries constitute a large portion of 
blast-related wounds in active military personnel, and because of their extensive 
variability and complexity, they are not amenable to standard treatments.[4,5]  
Interest in the use of human adipose stem cells (ASC) as a potential method 
to treat traumatic or blunt-force injuries has steadily grown over the last decade.  
Adipose-derived stem cells are a multipotent stem cell population found in 
abundance in adult humans, and they possess attributes well-suited for regenerative 
applications.  Autologous ASC are easily obtained through standard liposuction 
procedures, and can be expanded in culture. They have immunomodulatory 
properties and secrete vital growth factors, such as vascular endothelial growth 
factor (VEGF), which is an important molecule involved in the wound healing 
process.[6]  Recently, it was demonstrated that the addition of ASCs to a chronic 
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wound site decreased healing times, and that seeding ASCs on the surface of 
synthetic membranes showed an even greater benefit, increasing healing by 
50%.[7,8]  
Biomimetic frameworks that provide structural support and signaling cues 
derived from the extracellular matrix (ECM) may aid survival of transplanted cells. 
Poly(ethylene) glycol (PEG), a water soluble polymer, is currently used to extend the 
duration of interferon-alpha in humans as treatment for Hepatitis C, and can aid in 
the stimulation of neutrophil production in neutropenia.[9,10]  Hydrogels 
manufactured from this polymer can be functionalized to provide cell attachment and 
degradation sites, and may also be adapted for use in drug delivery systems and as 
substrates for cell transplantation.[11-13] The chemical versatility of PEG allows for 
the incorporation and modification of components that create a synthetic ECM 
closely mimicking an environment that, at the molecular level, can specifically 
interact with a given cell type in a directed manner.[14-16]  
One approach to encapsulation involves using thiol-functionalized multi-arm 
PEG groups that use divinyl sulfone as a crosslinker to polymerize the hydrogels 
through a Michael-type addition chemical reaction. This method avoids the need for 
a catalyst that has the potentially detrimental effect on encapsulated cells.[17,18] 
Furthermore, these PEG-based hydrogels possess the ability to incorporate peptides 
through thiol chemistry using a free cysteine.  Peptides containing Arg-Gly-Asp 
(RGD) sequences can serve as attachment sites for cells, via integrin binding, in the 
inert PEG gel.[19]  Sequences containing RGD have been shown to induce 
fibroblast spreading,[20] maintain embryonic stem cells[21], influence mineralization 
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by osteogenic cells,[22] promote the migration of smooth muscle cells through 
hydrogels[23], and regulate differentiation of various cell lines, such as endothelial 
cells and myoblasts.[24-27]  Modulation of the of RGD-containing sequence can 
influence survival, proliferation and differentiation, indicating that synthetic 
environments can be engineered to generate specific cell populations with specific 
functions.[18]  
In this study, we describe efforts to develop an encapsulating hydrogel for 
ASC that will remodel upon differentiation of ASCs to adipocytes.  Because 
adipocytes produce elevated levels of MMP-3 and MMP-10 (two members of the 
stromyelsin family of MMPs)[28,29], a scaffolding system was developed that used 
an MMP peptide cleavage site specific to MMPs 3/10 (GRCGRPKPQQ↓FFGLMG; 
hereafter MMPc) [30,31]. We hypothesize that the MMPc peptide may provide 
crosslinking abilities via the covalent incorporation at the C-terminus and 
hydrophobic interactions with PEG at the N-terminal amino acids, here cleavage of 
MMPc by secreted MMP 3/10 is proposed to alleviate these crosslinks and allow 
remodeling of the gel. We characterized ASCs encapsulated in this hydrogel in vitro, 
and show accelerated generation of lacunae or holes within the gel after 
differentiation.  
 
Materials and Methods 
Cell Culture 
 Adipose stem cells were isolated from donated lipoaspirate and purified using 
methods previously described elsewhere [18,32-34].  Briefly, lipoaspirate was 
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washed 5-10 times using phosphate buffered saline (PBS; pH 7.4) containing 1X 
penicillin streptomycin. Next, the lipoaspirate was digested using 0.15% collagenase 
type I solution (220.00 units/mg; Thermofisher, Carlsbad, CA).  The cell solution was 
then pelleted by centrifugation at 1000 x g for 10 min, and resuspended in a solution 
containing 160 mM ammonium chloride. Cells were then recentrifuged and 
resuspended in media containing 60% Dulbecco’s modified Eagle’s medium 
(DMEM; Thermofisher, Carlsbad, CA) with 10% FBS and 40% MesenPro medium 
(Thermofisher, Carlsbad, CA).  Finally, the cells were characterized using flow 
cytometery. Cultures were determined to be CD73, CD90, and CD105 positive, as 
well as CD45 and CD31 negative, consistent with the ASC immunophenotype 
defined by the guidelines set forth by the International Federation for Adipose 
Therapeutics and Science (IFATS) and the International Society for Cellular Therapy 
(ISCT).[35] 
 Cells at passage 2-4 were harvested from tissue culture flasks and 
encapsulate in a 10kDa PEG hydrogel (PEGworks Chapel Hill, NC) crosslinked 
using divinyl sulfone (DVS; Sigma Aldrich, St. Louis, MO) (PEG-DVS) as described 
preveiously [18]  A biotin tagged RGD containing peptide (VnRGD) 
(CGRCGKGGPQVTRGDVFTMPG-K(biotin)) derived from the full-length vitronectin 
amino acid sequence was incorporated to provide attachment sites for 
undifferentiated ASCs.  In some experiments, a peptide was incorporated that 
contained a site for cleavage by MMP3/10 (ac-GRCGRPKPQQ↓FFGLMG-NH2), 
derived from the sequence found in Substance P, a known substrate.[30]  Cells were 
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cultured in 3-dimensional (3D) hydrogels in either MesenPro or adipogenic 
differentiation media for 24 hrs., 4 or 12 weeks.[18] 
ELISA 
To examine amounts of cleaved biotin, an enzyme-linked immunosorbent 
assay (ELISA) was performed.  Here, ASCs were encapsulated into PEG-DVS 
hydrogels with VnRGD, in the presence of the MMPc cleavage peptide.  Hydrogels 
were grown in either adipogenic culture media or MesenPro media, media was then 
harvested 24hrs after polymerization and at 4 weeks.  Samples used to analyze 4 
week time points were harvested from media that was added 72hrs prior to the time 
point. Samples were diluted 1:2000, and the amount of biotin released into the 
media was determined using a Vitamin H ELISA kit (MDBioscience, St. Paul, MD; 
cat# M046019). 
Quantitative Real Time PCR 
After 4 weeks of culture, gels containing MMPc peptides were frozen in liquid 
nitrogen and manually homogenized in 1mL of TRIzol (ThermoFisher; Carlsbad, CA) 
containing 5µg/mL S. cerevisiae tRNA (Sigma Aldrich; Cat# R8508; St. Louis, MO) 
for 3 mins.[36]  Next, 100µl of chloroform was added and samples were centrifuged 
at 15,000 rpm for 18 min at 4°C. The aqueous phase was removed and 
recentrifuged at 15,000 rpm for 10 min at 4°C. The aqueous phase was then 
removed and an equal volume of 100% EtOH was added. The resultant solution was 
then added to RNeasy spin columns and subsequent steps followed in accordance 
with the RNeasy plus mini kit protocol (Qiagen; Cat# 74136; Hilden, Germany). RNA 
from two gels were combined during the elution step and used for cDNA synthesis 
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using an iScript cDNA synthesis kit (BioRad; Cat#; 1708891; Hercules, CA). 
Predesigned TaqMan (ThermoFisher; Canoga Park, CA) probes used to examine 
gene expression are shown in Table 3. 
Table 3. TaqMan probes used for gene expression analysis 
  Gene Gene Name Assay ID Marker cell type 
PPARG Peroxisome proliferator-activated receptor gamma Hs00234592_m1 Adipocyte 
ADIPOQ Adiponectin Hs00605917_m1 Adipocyte 
ACAN Aggrecan Hs00153936_m1 Chondrocyte 
ALPL Alkaline Phosphatase Hs01029144_m1 Osteocyte 
vWF von Willebrand factor Hs01109446_m1 Endothelial 
MMP3 Matrix metallopeptidase 3 (stromelysin 1) Hs00968305_m1 - 
  Gene Gene Name Assay ID Marker cell type 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs02758991_g1 Housekeeper 
ACTB Actin, beta Hs01060665_g1 Housekeeper 
GPI Glucose-6-phosphate isomerase Hs00976715_m1 Housekeeper 
 
Preparation and Immunocytochemistry 
 After 24hr., 4 or 12 weeks in culture samples were washed 3 x 5 min in PBS 
then immersion fixed in 4% paraformaldehyde in 0.1M sodium cacodylate (Electron 
Microscopy Sciences, Hatfield, PA) for 30 min at room temperature.  Samples were 
then cryo-protected using a gradient series of 10%, 20%, 30% sucrose in PBS for 2 
hr. each and placed in 40% sucrose overnight at 4°C.  The following day samples 
were immersed in optimal cutting temperature (OCT) media (Electron Microscopy 
Sciences, Hatfield, PA) on a rotator overnight at room temperature.  Finally, samples 
were embedded in OCT media, frozen using liquid nitrogen and sectioned at 20µm. 
 To identify the hydrogel, slides were immunostained using a streptavidin 
secondary antibody conjugated to 488 or 568 flurophore (1:100; Jackson 
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ImmunoResearch, West Grove, PA).  In order to further characterize developing 
ASCs, sections were stained using anti-PPAR gamma (1:50; Santa Cruz 
Biotechnology; Santa Cruz, CA; Cat: sc-271392), anti-MMP3 (1:50; EMD Millipore; 
Temecula, CA; MAB3306), anti-MAP2 (1:100; EMD Millipore; Temecula, CA) and 
Hoescht 33342 (1:5000; Thermofisher; Canoga Park; CA) for 1hr at room 
temperature in PBS containing 0.5% triton x-100, and 1% BSA (PBT). Samples were 
then rinsed 2 x 5 mins, in PBT and subsequently mounted using Prolong Gold 
(Invitrogen, Carlsbad CA) under a glass cover slip. 
Mosaic Acquisition and Image Registration 
 Digital micrographs were captured using an Olympus Fluoview 1000 laser 
scanning confocal microscope (Olympus America Inc., Center Valley, PA) equipped 
with a precision automated motorized stage (Applied Scientific Instrumentation Inc., 
Eugene, OR).  Using either an UPlanFLN 40x (N.A. 1.30) or an UPlanSApo 20x 
(N.A. 0.75) lens.  Datasets were collected as individual z-stacks captured at a pixel 
array of either 1024 x 1024 or 800 x 800.  Optical sections were collected at 1-µm 
intervals with a 5% overlap along the x and y-axes, finally resultant datasets were 
automatically maximally projected, aligned, and registered using Imago 1.5 
(Mayachitra Inc. Santa Barbara, CA) to yield wide-field high-resolution mosaics of 
the sectioned 3D hydrogels in a manner previously described.[37]  All datasets used 
for spatial analyses have been deposited to Bisque (Bio-Image Semantic Query 
User Environment) and are publically available for further interrogation with 
permission 
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(http://bisque.ece.ucsb.edu/client_service/view?resource=http://bisque.ece.ucsb.edu
/data_service/00-BCLMKCcAJrQ2XHUpXx4fnf).[38] 
Image Analysis 
 Images were analyzed using open source ImageJ software (National Institute 
of Health) to quantify both the number and size of holes present in each mosaic. 
Each z-stack was first projected as a 2D image, subsequently a threshold for 
detection of fluorescence was applied across all images analyzed. Images were then 
converted to a binary format and analyzed for particles using a set size (140-7000) 
and a circularity of (0.37-1) to ensure that only holes were included while edge 
artifacts were excluded from quantitative analyses.  Here, statistical significance was 
defined as p ≤ 0.05 using a one-tailed Student’s t-test.  
Animal Studies 
 In accordance with the University of California, Santa Barbara’s Institutional 
Animal Care and Use Committee, 2-month-old athymic mice were anesthetized with 
a ketamine/xylazine solution (100mg/kg each; Henry Schein; Melville, NY). A small 
incision was made on the mid-dorsal region of the animal and a pocket was formed 
using blunt dissection. A premade hydrogel containing undifferentiated ASCs was 
inserted. The incision was closed using surgical glue and the animals were allowed 
to recover on a water circulating heating pad. 4 and 12 weeks after the experimental 
transplantation, animals were euthanized by CO2 inhalation and the implants as well 
as surrounding tissue were excised and washed with PBS 3 x 5 min. Tissue samples 
were then processed for immunocytochemistry as previously described. 
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Results 
 In a previous study (Chapter 2), we described a simple, encapsulating RGD 
peptide hydrogel that supported survival and differentiation of ASCs. In this study, 
we sought to develop a hydrogel that will be remodeled during differentiation to 
provide spaces to accommodate adipocytes.  Because adipocytes produce elevated 
levels of MMP-3 and MMP-10 [28,29] , we incorporated peptides containing MMP 
cleavage sites recognized by these enzymes. The most promising peptide 
(GRCGRPKPQQ↓FFGLMG; hereafter MMPc), was selected for further study 
[30,31].  
After 4 weeks in maintenance media (MesenPro), 3D synthetic scaffolds with 
and without MMPc peptide showed no structural changes (Figs. 6A, B; green).  
Similarly, scaffolds that did not contain MMPc and cultured in adipogenic 
Figure 6. Remodeling of differentiated MMPc containing hydrogels. Gels kept in an 
undifferentiated state for 4 weeks of culture without (A) and with (B) MMPc peptide show very few 
holes. The differentiation of hydrogels alone, without the presence of MMPc (C) does not cause 
remodeling of the gel. Combining differentiation with the incorporation of MMPc peptide causes 
extensive remodeling of the hydrogel. The number of holes in each condition has been quantified 
in (E). The size of those holes has been quantified in (F). Scale bars = 500µm. 
	 75 
differentiation media for 4 weeks displayed no structural changes (Fig 6C). However, 
the inclusion of MMPc resulted in significant structural changes in the gels after 4 
weeks of adipogenic differentiation with an increased number of lacunae, or holes 
observed (Fig. 6D; green; asterisk, inset). After 4 weeks, no statistical significance in 
the average number of holes was observed between undifferentiated samples with 
and without MMPc.  However, after 4 weeks of differentiation there was a statistical 
significance in the average number of holes per z-stack between hydrogels that 
contained the cleavage peptide (13.83 holes/z-stack) and those that did not (5.03 
holes/z-stack) (Fig. 6E; p ≤ 0.001). Additionally, no statistical significance in the 
average area of holes per z-stack was observed between undifferentiated hydrogel 
with (0.04 mm2) and without (0.01 mm2) the cleavage peptide. The average area of 
holes in differentiated hydrogels with MMPc was significantly increased compared to 
differentiated gels without MMPc as well as both undifferentiated conditions (Fig. 6F; 
p ≤ 0.001).   
 To determine whether the ASCs were responsible for the generation of holes 
in the MMPc scaffolds, hydrogels were cultured for 4 weeks with and without 
undifferentiated ASCs and no structural changes were observed in number or sizes 
of holes (Figs. 7A, B; green).  Hydrogels containing MMPc that were differentiated 
for 4 weeks in the absence of ASCs also appeared structurally similar to those in 
undifferentiated conditions (Fig. 7C; green).  However, scaffolds containing 
differentiated ASCs in the presence of MMPc showed a markedly increased number 
of holes (Fig. 7D).   
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Upon quantification no statistical significant difference was observed in the 
number of holes per z-stack in hydrogels that were cultured in maintenance media 
with or without ASCs.  In contrast, gels that were differentiated in the presence of 
MMPc with ASCs showed a greater than 6-fold increase in the number of holes per 
Figure 7. Holes are dependent on the differentiation of cells in MMPc containing hydrogels. 
Undifferentiated gels containing MMPc, but without cells show no signs of remodeling (A).  The 
addition of cells, in an undifferentiated condition show no signs of remodeling (B).  Gels containing 
MMPc differentiated for 4 weeks in the absence of cells show no signs of remodeling (C).  Gels 
with MMPc, containing cells that have been differentiated for 4 weeks (D) show significant 
remodeling, quantified in E and F. Scale bars= 500µm	
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z-stack compared to those without ASCs (Fig. 7E; p ≤ 0.001). Similarly, the area of 
holes between undifferentiated conditions (i.e. with and without ASCs) showed no 
statistical significant difference (0.03 mm2 vs 0.04 mm2).  The area of holes in 
differentiated gels containing MMPc peptide in the presence of ASCs showed a 
distinct increase (Fig. 7F; 0.12 mm2 vs. 0.02 mm2; p ≤ 0.001).  
Voronoi domains were used to describe the 2-dimensional spatial 
organization of the ASCs across experimental conditions.  Manual annotations of 
Hoescht-stained nuclei were used and the Cartesian x-y coordinates on these nuclei 
 
Figure 8. Average Voronoi areas. Micrographs of hydrogels cultured for 4 weeks without MMPc (A 
and C) and with MMPc (E and G) in undifferentiated and differentiated conditions. Snapshots of 
Voronoi domain outlines (B, D, F, and H). Quantification of the average Voronoi area (I). 
Quantification of cell densities in all conditions (J). Scale bars = 100µm		
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were recorded in hydrogels cultured for 4 weeks (Figs. 8A, C, E, G). Voronoi domain 
diagrams were generated and their respective areas computed (Figs. 8B, D, F, H).  
In undifferentiated conditions Voronoi domain area averaged 6,420 um2.  By 
comparison hydrogels containing the MMPc peptide showed a statistically significant 
increase in the average area of Voronoi domains (10,221 um2, p ≤ 0.001) (Fig. 8I).  
Likewise, samples cultured in differentiation media also showed a statistically 
significant increase in the average Voronoi domain area between gels without MMPc 
(5,340 um2) and those with MMPc (7,648 um2; p ≤ 0.05).  To further support the 
changes observed in the average area of Voronoi domains in the undifferentiated 
conditions, cell densities were computed and it was determined that in samples not 
containing MMPc there was a statistically significant increase in the density of cells 
(156 cells/mm2) compared to those gels with MMPc (80 cells/mm2; p ≤ 0.001).  By 
contrast, samples cultured in differentiation media showed no statistical difference in 
cell density (124 cells/mm2; +MMPc) and (183 cells/mm2; -MMPc) (Fig. 8J).  Finally, 
a coefficient of variance analysis (i.e. standard deviation/mean of the Voronoi 
domains) was performed to determine whether there was cell clustering observed in 
any condition.  It was determined that no condition demonstrated an increased 
grouping of cells in 2D (Fig. 8K).   
Encapsulated cells were further analyzed using immunocytochemistry. Cells 
were clustered around the edges of the holes in the hydrogel (Figs. 9A, C, E; 
arrows). While ASCs that were differentiated for 4 weeks in samples with MMPc 
remained clustered near the edges of the holes in the remodeled gel, even in spaces 
that appeared devoid of PEG (Fig. 9G; asterisks).  Under these conditions, the gel 
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appeared to be thickened at the boundary of the holes, as indicated by biotin 
staining (green). To rule out trapping of streptavidin, sections were stained with 
hemotoxylin and eosin, which revealed a higher density of gel at the boundary of 
holes (Supplemental Figure 1). Additionally, cells in each condition had a rounded 
appearance, indicated by anti-MAP2 staining, a hallmark morphological appearance 
of adipocytes (Figs. 9B, D, F, H; red).[39]  
Adipose-derived stem cells that were undifferentiated in gels with the MMPc 
cleavage site showed only non-specific anti-PPAR gamma labeling compared to the 
elevated labeling observed in ASCs that had been differentiated for 4 weeks (Figs. 
10A-D).  Anti-PPAR gamma labeling appeared to display perinuclear localization in 
ASCs under differentiated conditions (Fig. 10D; arrows).  Additionally, 
immunolabeling for the MMP3/10 protein was also increased in the differentiated 
Figure 9. Cell Morphology in hydrogels +/- MMPc. Micrographs of hydrogels cultured for 4 weeks 
without (A-D) and with (E-H) MMPc, in undifferentiated and differentiated conditions. Arrows 
indicate protrusions of the cellular membrane. Asterisk indicates holes formed in the +MMPc 
Differentiated condition. Scale bars = 20µm	
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state (Figs. 10E-H).  In the differentiated state a majority of the ASCs were MMP 
3/10 immunopositive (Fig. 10H; arrows). Gene analysis determined a statistically 
significant increase in two adipogenic genes (PPARG and ADIPOQ) in differentiated 
samples. Chondrogenic and endothelial genes examined (ACAN and vWF 
Figure 10. Expression of PPARγ and MMP3/10 protein in MMPc containing hydrogels. There 
is no expression of PPARγ after 4 weeks of culture in undifferentiated conditions (A and B). 
Four weeks of adipogenic differentiation elicits expression of PPAR➌ (C and D – arrows). In 
undifferentiated conditions after 4 weeks of culture there is no expression of MMP3/10 (E and 
F). Expression in differentiated conditions at 4 weeks is observed (G and H – arrows). 
Quantification of gene expression shows that differentiated cultures show an increase in 
adipogenic markers, but not in chondrogenic, osteogenic, or endothelial markers and also 
show an increase in MMP3 expression (I). Release of biotin from the scaffolding into the 
media during culture duration shows that gels with MMPc that are differentiated are degrading 
(J). Scale bars = 20µm	
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respectively) showed no 
expression in either differentiated 
or undifferentiated conditions.  
Expression of MMP3 showed an 
increase in samples that were 
adipogenically differentiated 
compared to undifferentiated 
counterparts (Fig 10I).  
To investigate degradation 
of the system, we quantified 
biotin released into the media 
after adipocytic differentiation. 
Biotin is attached to the RGD 
peptide, which was covalently 
attached to the PEG backbone. A 
significant increase in the amount 
of biotin was detected at 4 weeks 
in gels with differentiated ASCs 
(1822.60 ng/ml), compared to the 
undifferentiated samples 
(1678.70 ng/ml)(Fig. 10J).  
 Samples cultured for 4 and 
12 weeks were used to examine 
Figure 11. Degradation of gels without MMPc over 12 
weeks. After 12 weeks of culture gels maintained in 
undifferentiated conditions show no increase in the 
number of holes present compared to 4 weeks (A and 
D). Gels that are differentiated for 12 weeks show a 
significant increase in the number (E) compared to 4 
weeks (B). After 4 weeks of growth in vivo there are no 
signs of degradation (C), but at 12 weeks holes are 
apparent (F). Samples that were grown for 4 weeks (G) 
and 12 weeks (H) in athymic mice. Quantification of the 
number (I) and size (J) of holes from 4 week in vitro 
samples.	
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the effects of long-term culture on the degradation of gels without the MMPc peptide. 
Adipose-derived stem cells that were maintained in an undifferentiated state for 12 
weeks showed no increase in the number of holes compared to 4 weeks (Figs. 11A, 
D, G). In contrast, adipogenically differentiated ASCs elicited degradation not seen 
at 4 weeks (Fig. 11B) in the absence of MMPc, after 12 weeks (Fig. 11E). The 
appearance of holes in the 12 week differentiated conditions indicates that the 
differentiation of the cells is a significant contributing factor in the remodeling of the 
synthetic scaffold.  A greater than four fold increase in the number of holes, as well 
as an increase in size was observed at 12 weeks (Figs. 11G-H).   
When hydrogels were subcutaneously implanted into nude mice for 4 and 12 
weeks similar trends in remodeling were observed. After 4 weeks there were very 
few holes apparent in the hydrogel (Fig. 11C) whereas at 12 weeks there was a 
trend towards an elevated number of holes (Fig. 11F). This increase suggests 
differentiation of the transplanted cells while in vivo.  
This time course appears to closely mimic the progression observed in vitro 
and indicates that 3D culture conditions are comparable to in vivo models. The 
consistency between in vitro and in vivo remodeling times may prove useful for 
providing insights into scaffold behavior and at the same time reducing the number 
of animal needed for pre-clinical experiments. 
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Discussion 
 Our previous work has demonstrated that the PEG-DVS hydrogel system 
allows for the survival and differentiation of ASCs into mature adipocytes (Chapter 
2).[18]  These PEG-based scaffolds have demonstrated robust biostability in culture, 
showing no significant degradation over a 1-month period. However, the ASCs were 
constrained in close proximity to the surrounding gel, which may not allow for 
diffusion of secreted ECM, optimal differentiation, or investiture of the vasculature 
after transplant. Therefore, we sought to modify the hydrogel to allow remodeling 
upon differentiation to generate spaces to accommodate adipose cells.  Research 
from a variety of labs have incorporated peptide crosslinks that are susceptible to 
enzymatic degradation by MMPs.[17,40-44]  These previous approaches most often 
utilize a peptide that includes two cysteine residues flanking an MMP cleavage site 
for common MMP collagenases, allowing for generic degradation. Collagenases 
comprise the largest known class of MMPs, and by utilizing these cleavage sites 
degradation of the hydrogel can be very rapid.   
We incorporated a novel MMP peptide containing the cleavage site 
recognized by MMP-3 and MMP-10, stromelysins which are known to be elevated in 
adipocytes. Surprisingly, we found that a peptide containing only a single cysteine 
residue (MMPc) permitted remodeling as encapsulated ASCs differentiate into 
mature adipocytes. Our data show that these functionalized scaffolds contained an 
increased number and size of lacunae or holes after differentiating the ASCs for 4 
weeks in culture, a phenomenon not seen in samples with undifferentiated ASCs. 
Furthermore, the remodeling occurred only in the presence of differentiated ASCs, 
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indicating that it is unlikely a result of a breakdown of the hydrogel over time or an 
artifact of long-term culture alone.  
Voronoi domains quantitatively showed the distribution of ASCs in 2-
dimensional space across experimental conditions, and that the incorporation of the 
MMPc site is correlated with the presence of larger Voronoi areas indicating that the 
cellular distribution in these degradable scaffolds varied from their counterparts. 
However, cell density in differentiated conditions was not altered by the inclusion of 
an MMPc site, indicating that the increase in area of Voronoi domains was not a 
result of a reduction in the number of ASCs present after 4 weeks of culture. 
Interestingly, the differentiation of these cells elicited an increase in density not 
observed in the undifferentiated samples (p ≤ 0.01). The increase in density may be 
indicative of increased cell viability due to the deposition of ECM by the 
differentiating cells, a process that may be absent in undifferentiated cultures. 
Finally, a coefficient of variation analysis was used to determine the relative 
distribution of ASCs throughout each condition revealing that no condition exhibited 
a unique distribution of cells (i.e., clustering). A homogeneous distribution of ASCs in 
a scaffolding system may be important in improving therapeutic approaches to tissue 
regeneration. 
General cellular morphology was examined by probing for the cytoskeletal 
marker MAP2. Anti-MAP2 labeling revealed that ASCs in an undifferentiated state in 
both the presence and absence of MMPc showed protrusions representing potential 
attachment sites to the hydrogel. These extensions were also noted in the 
differentiated samples without MMPc although to a lesser extent. However, the 
	 85 
hydrogels containing the MMPc site with differentiated ASCs displayed no visible 
protrusions emanating from ASCs. Cells in this condition showed a more rounded 
morphology, congruent with the typical phenotype of adipogenic cell 
differentiation.[39]  
Adipogenic differentiation of the ASCs was confirmed by the 
immunocytochemical presence of the nuclear receptor PPAR gamma (PPARG). At 
the transcription level, adipogenic differentiation of ASCs was examined via RT-
qPCR. Two genes commonly used to characterized adipose tissue are PPARG and 
ADIPOQ, here it was observed both increased in differentiated samples.  
Gene expression analysis for contaminating cell-types was also examined in 
differentiated samples; with no detectable level of chondrogenic (ACAN), or 
endothelial cell (vWF) genes observed, and statistically insignificant changes in an 
osteogenic (ALPL) gene. Increased expression of MMP3 was confirmed at both the 
gene and protein level in the differentiated condition and was not detected in the 
undifferentiated condition.  The increase in MMP3/10 expression (both protein and 
gene) supports the hypothesis that as ASCs in the hydrogels continue to 
differentiate into mature adipocytes they increase their expression of MMP3/10.  
Investigation into whether this remodeling occurs in the absence of the MMPc 
peptide revealed evidence of degradation after 12 weeks, indicated by the 
appearance and size of holes in the sectioned hydrogel. These holes were not found 
in undifferentiated conditions demonstrating that degradation is dependent on 
differentiation up to 12 weeks, and that these PEG-based hydrogels do not fully 
disintegrate over a 12 week period in culture. While the number of holes in the 
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undifferentiated condition was not increased from 4 to 12 weeks the size of the holes 
were significantly larger. This may indicate a small amount of natural differentiation 
of ASCs after long-term culture.  Hydrogels lacking the MMPc peptide implanted 
subcutaneously in athymic mice were still present at 4 and 12 week time points. 
There was also a clear demarcation between the implanted scaffold and animal 
tissue surrounding it, suggesting that the scaffolds are able to maintain their 
structure, thus allowing for systematic identification of implanted components.  There 
was evidence of ASCs present in the gels after 12 weeks showing the ability of 
these PEG hydrogels to support long-term cell survival. The presence of synthetic 
gel at 12 weeks indicates a slow degradation process in vivo. PEG hydrogels have 
been reported to degrade in vivo, with varying kinetics.[45] Scaffolds maintained in 
vivo exhibited similar trends to in vitro gels, with no significant holes present after 4 
weeks. However, after 12 weeks the number of holes was greatly increased. 
Remodeling appears to be present at 12 weeks, even in the absence of the MMPc 
peptide. This may signify differentiation of the ASCs in vivo, a desirable trait for 
tissue regeneration in order to reduce the amount of manipulation necessary prior to 
implantation.  
The variation in remodeling times depending on the presence of the cleavage 
peptide also affords this system versatility. By altering various aspects of the system, 
such as concentration of MMPc or cell density at time of encapsulation, this scaffold 
can potentially be modified to remodel and/or degrade in a time or cell dependent 
manner that is appropriate for the target tissue, ranging from weeks to several 
months. The generation of holes by the differentiated adipocytes not only provides a 
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supportive niche, but could aid in vascularization of the gel after implantation. 
Studies are underway to further characterize these gels after implantation in animal 
models.  
 
Conclusions 
Novel, encapsulating PEG hydrogels containing an Arg-Gly-Asp (RGD) 
attachment sequence in addition to a matrix metalloprotease 3 / 10 cleavage site 
(MMPc) supported ASC survival and showed a regulated remodeling triggered by 
adipogenic differentiation.  These RGD-MMPc hydrogels with encapsulated ASCs 
showed an increase in the number and area of lacunae or holes upon adipogenic 
differentiation, providing a niche for newly developed adipocytes. Tunable, 
biomimetic hydrogel scaffolds where remodeling of the gel is triggered by adipogenic 
differentiation may be useful in soft tissue regeneration.  
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Chapter IV 
Conclusion 
 In my opinion it has been an exciting privilege to work in the field of adult 
mesenchymal stem cells.  The boundless opportunities that this cell type provide to 
the treatment of human disease and injury makes this work all the more exciting.  As 
most of the non-scientific world knows mostly about embryonic stem cells working in 
this field has enabled me to open the eyes of many of that population to the benefits 
of potential stem cell therapies that don’t involve what they deem to be controversial.  
Through collaborations and funding from the California Institute for Regenerative 
Medicine (CIRM), I have been able to spread knowledge to an even broader 
audience than would have been possible without their support, and for this I feel 
exceptionally fortunate. 
 Work on developing synthetic scaffolds has become an area of increasing 
exploration in the field of tissue engineering. Creating environments that play an 
active role in the viability and differentiation of cells to be transplanted has become 
vital to the effectiveness of these regenerative therapies. The system described in 
this work enables engineering of the basic scaffold for different applications by 
expanding the possible uses of a simple system to include different target tissues 
and different treatment options. The use of cleavage sites increases the number of 
potential applications even further by introducing a mechanism for degradation and 
remodeling as a function of differentiation. In cases where shorter regeneration 
times are desirable, such as cases involving wound healing that seek to avoid 
extensive scaring a scaffolding system that degrades more quickly may be 
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beneficial, whereas tissues that require more extensive regeneration times, for 
example, deep ulcers, may require the synthetic environment to remain intact for a 
longer time.  Collectively, the results described here provide a variety of applications 
for a hydrogel scaffolding system that may be altered to expand the collection of 
uses this system might benefit. 
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Appendix 
 
 
Supplemental Figure 1: Histological stains of MMPc gels. Gels stained with Toluidine Blue 
show different distributions of nucleic acids present in undifferentiated samples (A) and 
differentiated samples (B). Hemotoxylin and Eosin staining of undifferentiated (C) and 
differentiated (D) samples shows altered distribution of hydrogel after adipogenic 
differentiation.	
